var title_f21_26_21920="Balance PI";
var content_f21_26_21920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Balance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Use a wobble board or balance disk to improve knee strength and balance ability. If a wobble board or balance disk is not available, try balancing on the affected leg while lifting the unaffected leg off the ground; do not hold onto any support. Hold this position for a count of 5 to 10. Rest and repeat 10 to 15 times. To increase the difficulty, raise the unaffected leg into the air.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21920=[""].join("\n");
var outline_f21_26_21920=null;
var title_f21_26_21921="Ultrasound guided biopsy machine";
var content_f21_26_21921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound guided biopsy machine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with permission of GE Healthcare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21921=[""].join("\n");
var outline_f21_26_21921=null;
var title_f21_26_21922="Persist fetal vasculature";
var content_f21_26_21922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Persistent fetal vasculature",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Persistent fetal vasculature (right eye). A typical presentation of esotropia, leukocoria, and microphthalmia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21922=[""].join("\n");
var outline_f21_26_21922=null;
var title_f21_26_21923="Methyl salicylate and menthol: Drug information";
var content_f21_26_21923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methyl salicylate and menthol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/55/13172?source=see_link\">",
"    see \"Methyl salicylate and menthol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15040943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Reports of Serious Burns Due to Topical Pain Relievers, FDA Issues Warning",
"     </span>",
"     <span class=\"collapsible-date\">",
"      September 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) is alerting the public that certain over-the-counter (OTC) topical pain relievers have been associated with rare cases of serious skin injuries (eg, first- to third-degree chemical burns) at the application site. In some cases, hospitalization has been required.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       OTC topical pain relievers are available as single- or combination-ingredient products that contain menthol, methyl salicylate, or capsaicin, and are marketed under brand names such as BenGay&reg;, Capzasin&reg;, Icy Hot&reg;, and Mentholatum&reg;. The formulations include creams, lotions, ointments, and patches.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Consumers who experience signs of skin injury (eg, pain, swelling, or blistering) following application of these products should discontinue their use and seek immediate medical attention. When recommending these pain relievers, healthcare providers should counsel patients about their appropriate use and the risk of burns.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm319353.htm\" target=\"_blank\">",
"        file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm319353.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BenGay&reg; [OTC];",
"     </li>",
"     <li>",
"      Icy Hot&reg; [OTC];",
"     </li>",
"     <li>",
"      Precise&reg; [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Arthritis Pain&reg; [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Jet Spray [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Massage Foam [OTC];",
"     </li>",
"     <li>",
"      Salonpas&reg; Pain Relief Patch&reg; [OTC];",
"     </li>",
"     <li>",
"      Thera-Gesic&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Thera-Gesic&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8116109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Topical;",
"     </li>",
"     <li>",
"      Salicylate;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8116430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain relief:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Balm, cream, foam, spray, stick: Apply to affected area; may repeat up to 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Apply to affected area; may repeat up to 3-4 times/day for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patch:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methyl salicylate 10% and menthol 1.5%: Apply 1 patch to affected area not more than 3-4 times daily; leave in place for no more than 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Methyl salicylate 10% and menthol 3%: Apply 1 patch to affected area and leave in place for up to 8-12 hours; do not exceed 1 patch/application. If pain still present, a second patch may be applied for up to 8-12 hours (maximum: 2 patches/24 hours; 3 days of consecutive use)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8116429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Pain relief:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Balm, cream, foam, spray, stick: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patch: Methyl salicylate 10% and menthol 1.5%: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F244835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Salonpas&reg; Massage Foam:  Methyl salicylate 10% and menthol 3% (118 mL)",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Salonpas&reg;  Jet Spray:  Methyl salicylate 10% and menthol 3% (118 mL) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Balm, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Icy Hot&reg; Balm: Methyl salicylate 29% and menthol 7.6% (99.2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BenGay&reg; Arthritis Formula: Methyl salicylate 30% and menthol 8% (57 g, 113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     BenGay&reg; Greaseless: Methyl salicylate 15% and menthol 10% (57 g, 113 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Icy Hot&reg;: Methyl salicylate 30% and menthol 10% (35.4 g, 85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Precise&reg;:  Methyl salicylate 30% and menthol 10% (75 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thera-Gesic&reg;: Methyl salicylate 15% and menthol 1% (85 g, 142 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Thera-Gesic&reg; Plus: Methyl salicylate 15% and menthol 4% (85 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patch, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Salonpas&reg; Arthritis Pain&reg;: Methyl salicylate 10% and menthol 3% (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Salonpas&reg; Pain Relief Patch&reg;: Methyl salicylate 10% and menthol 1.5% (3s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Salonpas&reg; Pain Relief Patch&reg;: Methyl salicylate 10% and menthol 3% (5s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stick, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Icy Hot&reg;: Methyl salicylate 30% and menthol 10% (49 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8116113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8116439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply topically; for external use only. Do not apply to wounds, rashes, damaged skin, mucous membranes or right after bathing. Wash area where applied prior to bandaging, covering or wrapping; do not bandage tightly. Do not use a heating pad after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Topical patch: Apply patch externally to clean and dry affected area. Backing film should be removed prior to application.  Patch should not be applied to face. Wash hands before and after application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F244836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of minor aches and pains of muscle and joints associated with arthritis, bruises, simple backache, sprains, and strains",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11394985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8116243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Dermatologic: Irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8116116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to menthol, methyl salicylate, aspirin, NSAIDS, other salicylates, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8116117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Topical patch: Self-medication (OTC use): Prior to self medication, patients should be instructed to contact a healthcare provider if they have had recurring stomach pain or upset, ulcers, bleeding problems, high blood pressure, heart or kidney disease, other serious medical problems, are currently taking a diuretic, anticoagulant, other NSAIDs, or are &ge;60 years of age. Recommended dosages and duration should not be exceeded, due to an increased risk of GI bleeding, MI, and stroke. Patients should stop use and consult a healthcare provider if symptoms get worse, newly appear, or persist for &gt;3 days; if rash, itching, or excessive skin irritation occurs, or if an allergic reaction occurs; if feeling faint, vomit blood or have bloody/black stools. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding. Patch is for external use only and should not be applied to wounds or damaged skin; do not use concurrently with other topical analgesics. May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients should be instructed to contact healthcare provider if rash, itching, or excessive skin irritation occurs, or symptoms persist for &gt;7 days. Products are for external use only and should not be applied to wounds or damaged skin.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8116114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate or well controlled studies in pregnant women. Use of the topical patch during the last 3 months of pregnancy is contraindicated by the manufacturer due to increased risk to the fetus and increased risk of complications during delivery.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Bengay Greaseless External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-15% (57 g): $3.90",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9504 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2143548A13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21923=[""].join("\n");
var outline_f21_26_21923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15040943\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116108\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116109\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116430\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116429\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F244835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116113\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116439\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F244836\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11394985\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116243\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116116\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116117\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116114\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322942\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9504\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9504|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/55/13172?source=related_link\">",
"      Methyl salicylate and menthol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21924="Developmental milestones 4 through 8 yrs B";
var content_f21_26_21924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 4 years, 0 months through 7 to 8 years (continued)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 591px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21924=[""].join("\n");
var outline_f21_26_21924=null;
var title_f21_26_21925="Darbepoetin alfa: Patient drug information";
var content_f21_26_21925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Darbepoetin alfa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     see \"Darbepoetin alfa: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21175?source=see_link\">",
"     see \"Darbepoetin alfa: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aranesp&reg;;",
"     </li>",
"     <li>",
"      Aranesp&reg; SingleJect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aranesp&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of heart attack, stroke, heart failure, blood clots, tumor growth, and death. People with higher red blood cell counts or having surgery have more chance of getting these problems. Your doctor will need to watch your blood cell counts and follow you closely to change the dose to match your body's needs. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705931",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cancer patients can only get this drug if doctors or hospitals are in the ESA APPRISE Oncology Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3509451",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help avoid the need for blood transfusions.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to darbepoetin alfa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3509462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a kind of anemia called Pure Red Cell Aplasia (PRCA).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a latex allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High or low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Iron is often needed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not shake.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12355 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21925=[""].join("\n");
var outline_f21_26_21925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030002\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030004\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030003\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030008\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030009\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030011\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030006\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030007\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030012\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030013\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=related_link\">",
"      Darbepoetin alfa: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/43/21175?source=related_link\">",
"      Darbepoetin alfa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21926="Hypochondriasis: Treatment and prognosis";
var content_f21_26_21926=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypochondriasis: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21926/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21926/contributors\">",
"     James L Levenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21926/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21926/contributors\">",
"     Joel Dimsdale, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21926/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21926/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/26/21926/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4695842\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and psychiatric care of hypochondriasis combines strategies for patient management with specific therapeutic interventions. However, many patients do not respond and have a poor prognosis.",
"   </p>",
"   <p>",
"    This topic reviews the treatment and prognosis of hypochondriasis. The epidemiology, clinical presentation, assessment, and diagnosis of hypochondriasis are discussed separately, as are the clinical features, medical evaluation, and treatment of somatization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link\">",
"     \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link\">",
"     \"Somatization: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695850\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core clinical feature of hypochondriasis is persistent preoccupation with having a serious medical illness despite appropriate medical evaluation and reassurance. The diagnosis is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef68413 \" href=\"UTD.htm?20/24/20875\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical presentation and diagnosis of hypochondriasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link&amp;anchor=H7947242#H7947242\">",
"     \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link&amp;anchor=H7947249#H7947249\">",
"     \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694989\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical and psychiatric care of hypochondriasis combines strategies for patient management with specific therapeutic interventions. The primary care clinician generally plays the central role in managing patients, and a mental health clinician may serve as a consultant and provide psychotherapy or pharmacotherapy.",
"   </p>",
"   <p>",
"    First-line treatment for hypochondriasis is psychotherapy, which has been studied more than pharmacotherapy. In particular, randomized trials have found cognitive-behavioral therapy (CBT) is efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, pharmacotherapy is a reasonable option if psychotherapy is unavailable, ineffective, or refused. Some patients fear medications, especially adverse effects and dependency, and may prefer CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/5\">",
"     5",
"    </a>",
"    ]. The combination of psychotherapy and pharmacotherapy has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4694996\">",
"    <span class=\"h2\">",
"     Approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal in managing hypochondriasis is to improve coping with symptoms rather than eliminate them [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The clinician should focus upon caring rather than curing, while reassuring the patient that the symptoms are &ldquo;real&rdquo; and will receive appropriate evaluation to identify their cause. Patients should feel that their concerns are understood and not dismissed as &ldquo;all in their head.&rdquo; A key part of management is to regularly schedule outpatient primary care visits that are not contingent upon active symptoms. Reassurance is helpful to many patients, but must be carefully dosed and targeted [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Facile or excessive reassurance may exacerbate disease fears, or cause patients to feel their physician has not listened or taken their concerns seriously. Unnecessary diagnostic tests, specialist referrals, and treatments should be avoided. The clinician should taper and discontinue unnecessary medications, especially those that are potentially addictive; however, this is best attempted after establishing a good clinician-patient relationship.",
"   </p>",
"   <p>",
"    It may be useful to address the quality of the clinician-patient relationship, which is often problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/8\">",
"     8",
"    </a>",
"    ]. A review found that patients with hypochondriasis often feel ignored by and speak disparagingly of their physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, self-report measures completed by 310 family medicine patients found that hypochondriacal symptoms were inversely correlated with the quality of the physician-patient relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/10\">",
"     10",
"    </a>",
"    ]. Addressing the relationship focuses upon the process of the patient and clinician working together, rather than the specifics of the patient&rsquo;s symptoms. As an example, patients can be asked to candidly describe their expectations about treatment and their feelings about the care they are receiving.",
"   </p>",
"   <p>",
"    Additional information about patient management is discussed separately within the context of somatization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link&amp;anchor=H3#H3\">",
"     \"Somatization: Treatment and prognosis\", section on 'General principles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=see_link&amp;anchor=H4#H4\">",
"     \"Somatization: Treatment and prognosis\", section on 'Structure of visits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695003\">",
"    <span class=\"h2\">",
"     Psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective treatment for hypochondriasis is psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. A meta-analysis of five randomized trials (247 patients with hypochondriasis) found that hypochondriacal thoughts and behaviors improved significantly more in patients who received psychotherapy compared to the control condition (waiting list, usual medical care, or placebo pill) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical effect was large, and symptoms of anxiety, depression, and physical distress also improved significantly more with psychotherapy. The psychotherapies consisted of cognitive therapy, behavioral therapy, cognitive-behavioral therapy, behavioral stress management, or psychoeducation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695010\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is the treatment of choice for hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Response to CBT may be more favorable in patients with less severe hypochondriacal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/11\">",
"     11",
"    </a>",
"    ]. A practical guide for treating hypochondriasis with CBT is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef53858 \" href=\"UTD.htm?25/39/26237\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    CBT combines cognitive therapy and behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3\">",
"     3",
"    </a>",
"    ]. Cognitive therapy attempts to modify the patient&rsquo;s dysfunctional thoughts, beliefs, and attitudes (eg, good health is a symptom-free state). Behavioral therapy focuses upon modifying the patient&rsquo;s problematic behavioral responses (eg, avoidant behaviors) to either environmental stimuli or dysfunctional thoughts, and may include exposure plus response prevention, as well as relaxation techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In many instances, cognitive therapy and behavioral therapy each include elements of the other therapy. Cognitive therapy or behavioral therapy can be used alone to treat hypochondriasis; however, clinicians typically use CBT, which has been studied more often.",
"   </p>",
"   <p>",
"    A randomized trial compared CBT (six weekly sessions) with usual medical care in 187 patients with hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/6\">",
"     6",
"    </a>",
"    ]. At the 12-month follow-up, CBT patients had significantly greater reductions of hypochondriacal beliefs and attitudes, anxiety, and psychosocial impairment. Other randomized trials have found similar benefits for CBT, along with reduced symptoms of anxiety and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/4,13-16\">",
"     4,13-16",
"    </a>",
"    ]. However, many of the trials were limited because the control condition consisted of treatment as usual or a waiting list, rather than an active psychotherapy comparator to control for the nonspecific aspects of psychotherapy.",
"   </p>",
"   <p>",
"    CBT typically includes psychoeducation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, the clinician can explain that some somatic symptoms are not necessarily caused by a serious medical illness, but instead may be due to underlying physiologic mechanisms such as autonomic arousal, muscle tension, hyperventilation, vascular changes, inactivity, sleep disturbance, and brain cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/2\">",
"     2",
"    </a>",
"    ]. Some authorities emphasize the educational nature of CBT, referring to it as a course on the perception of physical symptoms, and likening the therapeutic relationship to that of teacher and student more than clinician and patient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/12\">",
"     12",
"    </a>",
"    ]. The purpose is to reduce the stigma of psychiatric treatment and patient resistance.",
"   </p>",
"   <p>",
"    CBT is usually delivered according to a treatment manual that specifies the procedures to be used and content of each session. Most patients receive individual (one to one) therapy over 6 to 20 weekly sessions, each lasting 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3\">",
"     3",
"    </a>",
"    ]. A group format with five to nine patients is also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/12,17\">",
"     12,17",
"    </a>",
"    ], as is an internet-based format [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients learn skills that they are expected to practice and adapt to their own situation.",
"   </p>",
"   <p>",
"    No randomized trials of maintenance CBT have been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695031\">",
"    <span class=\"h4\">",
"     Cognitive-behavioral therapy compared with other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT may be superior to psychodynamic psychotherapy and comparable to behavioral stress management for treating hypochondriasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One randomized trial with 72 patients found that symptoms of hypochondriasis, anxiety, and depression improved significantly more with 16 sessions of CBT (augmented with mindfulness training), compared with 16 sessions of brief psychodynamic psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/17\">",
"       17",
"      </a>",
"      ]. Most differences persisted over follow-up lasting 12 months.",
"     </li>",
"     <li>",
"      One randomized trial with 46 patients found that at the end of treatment, symptoms of hypochondriasis improved significantly more with 19 sessions of cognitive therapy than 19 sessions of behavioral stress management [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/18\">",
"       18",
"      </a>",
"      ]. However, there was little difference between the groups at the 12-month follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H411577\">",
"    <span class=\"h4\">",
"     Cognitive-behavioral therapy compared with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear if CBT is superior to pharmacotherapy for treating hypochondriasis. CBT may be more effective than pharmacotherapy in the short-term, but the difference appears to decrease over time.",
"   </p>",
"   <p>",
"    One 16-week randomized trial compared CBT (between 6 to 16 sessions, depending upon the speed of recovery) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (20 to 60 mg per day) in 74 patients with hypochondriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/14\">",
"     14",
"    </a>",
"    ]. Response (a one-standard deviation decrease from the mean baseline hypochondriasis symptoms score) occurred in more patients who received CBT compared with paroxetine (45 versus 30 percent). Although this difference was not statistically significant, if real, would be clinically meaningful. Attrition did not differ between treatments. Follow-up 18 months after treatment found that hypochondriacal symptoms did not differ significantly between CBT and paroxetine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695038\">",
"    <span class=\"h3\">",
"     Other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among other psychotherapies that have been evaluated for treating hypochondriasis, behavioral stress management may be effective.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Behavioral stress management",
"      </strong>",
"      &ndash; Behavioral stress management combines elements of relaxation, problem-solving, assertiveness training, and time management. A randomized trial compared 19 sessions of this therapy with a waiting list control in 32 patients with hypochondriasis, and found that hypochondriacal thoughts and behaviors improved significantly more in patients who received behavioral stress management [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3,18\">",
"       3,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Brief psychodynamic psychotherapy",
"      </strong>",
"      &ndash; Brief psychodynamic psychotherapy attempts to modify symptoms by exploring their unconscious meaning. A randomized trial compared 16 sessions of psychodynamic therapy with a waiting list control in 56 patients with hypochondriasis, and found no significant difference in reducing hypochondriacal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Psychoeducation",
"      </strong>",
"      &ndash; Psychoeducation consists of information and reassurance about the illness. A randomized trial compared eight sessions of psychoeducation with a waiting list control in 20 patients with hypochondriasis, and found no significant difference in reducing hypochondriacal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/3,20\">",
"       3,20",
"      </a>",
"      ]. However, psychoeducation is usually part of CBT. (See",
"      <a class=\"local\" href=\"#H4695010\">",
"       'Cognitive-behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695045\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonin reuptake inhibitors (SSRIs) are efficacious for treating hypochondriasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 24-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (20 to 80 mg per day) with placebo in 45 patients with hypochondriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/21\">",
"       21",
"      </a>",
"      ]. Response (a rating of much or very much improved) occurred in significantly more patients who received fluoxetine compared with placebo (54 versus 24 percent). Symptoms of anxiety and depression did not differ significantly between treatments, nor did attrition.",
"     </li>",
"     <li>",
"      A 16-week randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      (20 to 60 mg per day) with placebo in 72 patients with hypochondriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/14\">",
"       14",
"      </a>",
"      ]. Response (a one-standard deviation decrease from the mean baseline hypochondriasis symptoms score) occurred in more patients who received paroxetine compared with placebo (30 versus 14 percent). Although the difference between treatments was not statistically significant, if real, would be clinically meaningful. Symptoms of anxiety and depression did not appear to differ between treatments. Fatigue and sexual dysfunction occurred in significantly more patients who received paroxetine; heart palpitations occurred in significantly more patients who received placebo. Attrition did not differ between treatments. It appeared that the benefit of paroxetine was sustained for up to 18 months after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No randomized trials of maintenance pharmacotherapy have been conducted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695052\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypochondriasis is often chronic with fluctuating symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/1,22\">",
"     1,22",
"    </a>",
"    ]. However, patients with a shorter duration of hypochondriasis may have a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of six prospective observational studies (412 primary care patients with hypochondriasis), remission occurred in 33 to 85 percent of the patients during follow-up ranging from approximately one to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/23\">",
"     23",
"    </a>",
"    ]. Baseline factors that were associated with remission included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer somatic symptoms",
"     </li>",
"     <li>",
"      Milder cognitive and behavioral symptoms",
"     </li>",
"     <li>",
"      Shorter duration of illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remission rate did not appear to be related to comorbid anxiety or depression, or length of follow-up.",
"   </p>",
"   <p>",
"    A subsequent observational study of 45 patients who presented for treatment of hypochondriasis found that after 4 to 16 years (mean 9 years), 60 percent no longer met criteria for the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/24\">",
"     24",
"    </a>",
"    ]. Improvement was significantly associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Shorter duration of hypochondriasis prior to initial contact for treatment",
"     </li>",
"     <li>",
"      No history of childhood physical punishment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypochondriasis can result in disability and invalidism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. In a systematic review of six community-based or primary care studies, hypochondriasis was associated with increased disability in each study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/25\">",
"     25",
"    </a>",
"    ]. A subsequent study examined disability pension awards in 6819 individuals assessed for health anxiety (fears about illness) and followed for up to six years. [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21926/abstract/26\">",
"     26",
"    </a>",
"    ]. After adjusting for confounds (income; education; general medical and psychiatric disorders; and depressive, anxiety, and somatic symptoms), severe health anxiety was significantly associated with a subsequent disability pension award (OR 2.3, 95% CI 1.4-3.9). In addition, there was a dose-response relationship, such that greater levels of health anxiety were significantly related to an increased probability of receiving a disability award.",
"   </p>",
"   <p>",
"    It is not known whether remitted patients are at risk for recurrence of hypochondriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4695834\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The core clinical feature of hypochondriasis is persistent preoccupation with having a serious medical illness despite appropriate medical evaluation and reassurance. The diagnosis is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef68413 \" href=\"UTD.htm?20/24/20875\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link&amp;anchor=H7947242#H7947242\">",
"       \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\", section on 'Clinical presentation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=see_link&amp;anchor=H7947249#H7947249\">",
"       \"Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical and psychiatric care of hypochondriasis combines strategies for patient management with specific therapeutic interventions. (See",
"      <a class=\"local\" href=\"#H4694989\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary goal in managing hypochondriasis is to improve coping with symptoms rather than eliminate them (caring rather than curing). A key part of management is to regularly schedule outpatient primary care visits that are not contingent upon active symptoms. Carefully dosed and targeted reassurance may be helpful. Unnecessary diagnostic tests, specialist referrals, and treatments should be avoided. It may also be useful to address the quality of the clinician-patient relationship. &nbsp;(See",
"      <a class=\"local\" href=\"#H4694996\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several specific therapeutic interventions can alleviate symptoms. For patients with moderate to severe hypochondriasis, we recommend treatment with psychotherapy or pharmacotherapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4694989\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychotherapy is first-line treatment to reduce hypochondriacal symptoms. For patients with hypochondriasis, we suggest cognitive-behavioral therapy (CBT) rather than other psychotherapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A practical guide for using CBT is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef53858 \" href=\"UTD.htm?25/39/26237\">",
"       table 2",
"      </a>",
"      ). Behavioral stress management is a reasonable alternative for patients who do not respond to CBT. (See",
"      <a class=\"local\" href=\"#H4695010\">",
"       'Cognitive-behavioral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4695038\">",
"       'Other psychotherapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A selective serotonin reuptake inhibitor (SSRI) can be beneficial for patients with hypochondriasis if psychotherapy is unavailable, ineffective, or refused.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      have each been studied. (See",
"      <a class=\"local\" href=\"#H4695045\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypochondriasis is often chronic and disabling. (See",
"      <a class=\"local\" href=\"#H4695052\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     Abbey SE, Wulsin L, Levenson JL. Somatization and somatoform disorders. In: The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, American Psychiatric Publishing, Inc., Washington, DC 2011. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/3\">",
"      Thomson AB, Page LA. Psychotherapies for hypochondriasis. Cochrane Database Syst Rev 2007; :CD006520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/4\">",
"      Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/5\">",
"      Walker J, Vincent N, Furer P, et al. Treatment preference in hypochondriasis. J Behav Ther Exp Psychiatry 1999; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/6\">",
"      Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA 2004; 291:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/7\">",
"      Abramowitz JS, Braddock AE. Hypochondriasis: conceptualization, treatment, and relationship to obsessive-compulsive disorder. Psychiatr Clin North Am 2006; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/8\">",
"      Page LA, Wessely S. Medically unexplained symptoms: exacerbating factors in the doctor-patient encounter. J R Soc Med 2003; 96:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/9\">",
"      Barsky AJ. Clinical practice. The patient with hypochondriasis. N Engl J Med 2001; 345:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/10\">",
"      Noyes R Jr, Longley SL, Langbehn DR, et al. Hypochondriacal symptoms associated with a less therapeutic physician-patient relationship. Psychiatry 2010; 73:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/11\">",
"      Hiller W, Leibbrand R, Rief W, Fichter MM. Predictors of course and outcome in hypochondriasis after cognitive-behavioral treatment. Psychother Psychosom 2002; 71:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/12\">",
"      Barsky AJ, Geringer E, Wool CA. A cognitive-educational treatment for hypochondriasis. Gen Hosp Psychiatry 1988; 10:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/13\">",
"      Visser S, Bouman TK. The treatment of hypochondriasis: exposure plus response prevention vs cognitive therapy. Behav Res Ther 2001; 39:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/14\">",
"      Greeven A, van Balkom AJ, Visser S, et al. Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. Am J Psychiatry 2007; 164:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/15\">",
"      Seivewright H, Green J, Salkovskis P, et al. Cognitive-behavioural therapy for health anxiety in a genitourinary medicine clinic: randomised controlled trial. Br J Psychiatry 2008; 193:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/16\">",
"      Hedman E, Andersson G, Andersson E, et al. Internet-based cognitive-behavioural therapy for severe health anxiety: randomised controlled trial. Br J Psychiatry 2011; 198:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/17\">",
"      S&oslash;rensen P, Birket-Smith M, Wattar U, et al. A randomized clinical trial of cognitive behavioural therapy versus short-term psychodynamic psychotherapy versus no intervention for patients with hypochondriasis. Psychol Med 2011; 41:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/18\">",
"      Clark DM, Salkovskis PM, Hackmann A, et al. Two psychological treatments for hypochondriasis. A randomised controlled trial. Br J Psychiatry 1998; 173:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/19\">",
"      Greeven A, van Balkom AJ, van der Leeden R, et al. Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up. J Behav Ther Exp Psychiatry 2009; 40:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/20\">",
"      Fava GA, Grandi S, Rafanelli C, et al. Explanatory therapy in hypochondriasis. J Clin Psychiatry 2000; 61:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/21\">",
"      Fallon BA, Petkova E, Skritskaya N, et al. A double-masked, placebo-controlled study of fluoxetine for hypochondriasis. J Clin Psychopharmacol 2008; 28:638.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/23\">",
"      olde Hartman TC, Borghuis MS, Lucassen PL, et al. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. J Psychosom Res 2009; 66:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/24\">",
"      Schweitzer PJ, Zafar U, Pavlicova M, Fallon BA. Long-term follow-up of hypochondriasis after selective serotonin reuptake inhibitor treatment. J Clin Psychopharmacol 2011; 31:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/25\">",
"      Creed F, Barsky A. A systematic review of the epidemiology of somatisation disorder and hypochondriasis. J Psychosom Res 2004; 56:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21926/abstract/26\">",
"      Mykletun A, Heradstveit O, Eriksen K, et al. Health anxiety and disability pension award: The HUSK Study. Psychosom Med 2009; 71:353.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16260 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21926=[""].join("\n");
var outline_f21_26_21926=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4695834\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695842\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695850\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4694989\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4694996\">",
"      Approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4695003\">",
"      Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4695010\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4695031\">",
"      Cognitive-behavioral therapy compared with other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H411577\">",
"      Cognitive-behavioral therapy compared with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4695038\">",
"      - Other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4695045\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695052\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4695834\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16260|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/24/20875\" title=\"table 1\">",
"      Dx criteria hypochondria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/39/26237\" title=\"table 2\">",
"      A practical guide for treating hypochondriasis with CBT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/392?source=related_link\">",
"      Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18984?source=related_link\">",
"      Somatization: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21927="Oxygen conserving devices";
var content_f21_26_21927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygen conserving devices",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Brian L Tiep, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Rick Carter, PhD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21927/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21927/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/26/21927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The functional disability experienced by patients with severe pulmonary disease relates both to their physiological impairment and their inability to adapt and maintain a normal lifestyle. As patients develop a medical need for supplemental oxygen, breathlessness and lack of energy are compounded by the increased demand of carrying oxygen equipment.",
"   </p>",
"   <p>",
"    Oxygen conserving devices have been introduced as a means of making oxygen therapy more efficient, more portable, and less intrusive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, hypoxemia can be prevented more readily in those patients with high oxygen flow requirements by using oxygen conserving devices, such as reservoir cannulas and transtracheal catheters. Escalating costs and reduced reimbursement have also fostered the availability of these systems.",
"   </p>",
"   <p>",
"    This review will compare traditional, continuous flow oxygen delivery by nasal cannula with a variety of oxygen conserving devices. The indications for long-term supplemental oxygen, the use of oxygen in hypercapnic patients, and issues regarding oxygen therapy during air travel are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONTINUOUS FLOW NASAL CANNULA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous flow nasal cannula oxygen delivery via nasal prongs is the standard against which all developments or improvements should be compared [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/3\">",
"     3",
"    </a>",
"    ]. The nasal cannula is universal and generally well accepted by patients and the public alike, and its effectiveness in meeting the oxygen needs of the stable chronic lung disease patient is essentially unquestioned. However, it is inefficient, as only a small percentage of the oxygen delivered to the nose actually reaches the alveoli.",
"   </p>",
"   <p>",
"    Oxygen flowing through the standard nasal cannula is nearly 100 percent pure. However, the patient actually receives a blend of pure oxygen and room air. In fact, a much larger volume of inspired atmospheric air, containing 20.9 percent oxygen, is entrained with the oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/4\">",
"     4",
"    </a>",
"    ]. The resultant inspiratory oxygen concentrations via standard flow settings are approximated in the figure (",
"    <a class=\"graphic graphic_figure graphicRef60292 \" href=\"UTD.htm?4/45/4830\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Assuming the most effective oxygen delivery occurs in the first 200 msec of inspiration, the fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) can be calculated and expressed as a percentage (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?34/7/34928?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). For example, the typical flow setting of 2",
"    <span class=\"nowrap\">",
"     L/minute",
"    </span>",
"    (min) would raise the FiO",
"    <sub>",
"     2",
"    </sub>",
"    to about 28 percent. This is a small amount of oxygen enrichment; however, it adequately corrects hypoxemia in most patients during rest [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPES OF OXYGEN CONSERVING DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of devices for enhancing the efficacy of oxygen therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reservoir cannulas",
"     </li>",
"     <li>",
"      Transtracheal catheters",
"     </li>",
"     <li>",
"      Demand oxygen pulsing devices",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each device meets the goal of improving oxygen delivery, but each has unique features that recommend for or against its use in the individual patient (",
"    <a class=\"graphic graphic_table graphicRef70691 \" href=\"UTD.htm?27/19/27963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reservoir cannulas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reservoir cannulas function by storing oxygen during exhalation, making that oxygen available as a bolus upon the onset of the next inhalation. Oxygen is conserved because the patient can be adequately saturated on a substantially reduced oxygen flow. Reservoir cannulas are particularly useful in patients who require a flow rate of oxygen 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    or higher.",
"   </p>",
"   <p>",
"    These cannulas are available in two configurations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A moustache configuration (Oxymizer",
"      <sup>",
"       &reg;",
"      </sup>",
"      ), in which the reservoir is located directly beneath the nose [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/6\">",
"       6",
"      </a>",
"      ]. A thin, compliant membrane in the reservoir is pushed forward during exhalation, creating a chamber between the membrane and the posterior wall (",
"      <a class=\"graphic graphic_figure graphicRef51350 \" href=\"UTD.htm?25/30/26081\">",
"       figure 2",
"      </a>",
"      ). This enables oxygen to be stored during most of exhalation. When the patient is ready to inhale,",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      receives the stored oxygen along with the continuously flowing supply oxygen.",
"     </li>",
"     <li>",
"      A pendant configuration (Oxymizer Pendant",
"      <sup>",
"       &reg;",
"      </sup>",
"      ), in which oxygen is stored in a reservoir located on the anterior chest [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/7\">",
"       7",
"      </a>",
"      ]. The reservoir membrane is pushed forward during exhalation, creating a chamber. This enables oxygen to be stored during exhalation in the reservoir. When the patient is ready to inhale,",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      receives the stored oxygen along with the continuously flowing supply oxygen, increasing the percent oxygen in the air that the patient inhales.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both reservoir cannulas are simple, reliable, inexpensive, and disposable. They operate in response to the patient's nasal airflow. While the efficacy of both cannulas is similar, there are differences in design that affect patient preference:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Oxymizer tends to be more comfortable than the Pendant and, in some cases, more comfortable than the standard nasal cannula. However, it is noticeable on the face, causing some patients to refuse to wear it.",
"     </li>",
"     <li>",
"      The Pendant is less noticeable. Previous pendant configurations utilized ear loops and wide tubing that some found to be uncomfortable. The present configuration has thinner tubing and no ear loops, thereby improving acceptance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both devices are partial rebreathing systems; as they return some of the patient's warmed expired air with elevated moisture, they effectively increase the relative humidity of the inhaled oxygen.",
"   </p>",
"   <p>",
"    Reservoir cannulas can be used by patients with high flow requirements because they improve the efficacy of oxygen delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/8\">",
"     8",
"    </a>",
"    ]. In the inpatient setting, reservoir cannulas have been used as a transition device from the Venturi mask, since they are less intrusive and facilitate eating and communication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/9\">",
"     9",
"    </a>",
"    ]. In the home setting, oxygen cylinders with limited storage and oxygen concentrators with limited flow range present barriers for patients on long-term oxygen. This is particularly true when the flow requirements reach beyond 6",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    Reservoir cannulas may enable patients with high flow requirements to live at home and maintain adequate oxygen saturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transtracheal catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of oxygen by transtracheal catheter is discussed elsewhere in detail. It is also mentioned here for comparison with the other conserving devices (",
"    <a class=\"graphic graphic_table graphicRef70691 \" href=\"UTD.htm?27/19/27963\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=see_link\">",
"     \"Transtracheal oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transtracheal catheters function by delivering oxygen directly into the trachea through a small opening in the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Continuously flowing oxygen is stored in the upper airways and trachea toward the end of exhalation and is delivered during early inhalation along with supply oxygen, bypassing a portion of the dead space of the upper airways. Additionally, the initial dead space of respiration is reduced, because the enriched oxygen is delivered to anatomic dead space; this in turn may reduce the work of breathing (",
"    <a class=\"graphic graphic_table graphicRef76455 \" href=\"UTD.htm?11/20/11595\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Like reservoir cannulas, transtracheal catheters have been successfully utilized to oxygenate patients with refractory hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Demand oxygen pulsing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Demand oxygen pulsing devices were developed to conserve oxygen flow and improve patient mobility outside the home. These devices have small reservoirs that supply a metered amount of oxygen only during inspiration, thus extending tank life. Different technological features have been used to optimize the size of the oxygen bolus and the delivery efficiency.",
"   </p>",
"   <p>",
"    Interposed between the pressurized oxygen source and the nasal cannula, these devices consist of a sensor, logic circuitry, and a valve (",
"    <a class=\"graphic graphic_figure graphicRef69597 \" href=\"UTD.htm?3/42/3744\">",
"     figure 3",
"    </a>",
"    ). The patient's inspiratory flow is detected through the nasal cannula or transtracheal catheter as a pressure swing; the valve then opens and delivers a short pulse of nearly 100 percent oxygen. The aim is to discharge all oxygen during the earliest part of inhalation, when it can participate in alveolar gas exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason that oxygen is provided early during the inspiratory cycle is explained in the model of inspiration shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef79819 \" href=\"UTD.htm?25/40/26254\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/4\">",
"     4",
"    </a>",
"    ]. Assuming a tidal volume of 450 mL, the first gas to reach the alveoli is the 150 mL of oxygen-poor gas (end expiratory gas) already occupying the airways; this is followed by 300 mL of inspired room air expected to reach the alveoli. The final 150 mL of inspired gas is destined to fill the airways at the end of inspiration, never reaching the alveoli (becoming the anatomic dead space gas). Thus, only the middle 300 mL of inhaled gas reaches the alveoli to enrich alveolar air with supplemental oxygen. The figure shows that airflow slows at the end of inspiration, so that dead space inspiration occupies a disproportionate 50 percent of inspiratory time (",
"    <a class=\"graphic graphic_figure graphicRef51871 \" href=\"UTD.htm?4/37/4688\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study, for example, demonstrated that nasal oxygen delivered incrementally earlier in inhalation progressively increased oxygen saturation (",
"    <a class=\"graphic graphic_figure graphicRef73365 \" href=\"UTD.htm?8/30/8685\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/14\">",
"     14",
"    </a>",
"    ]. Consequently, oxygen delivery should occur within the first 0.5 second of inspiration, prior to the last 150 mL, as oxygen delivered beyond this time will not participate fully in alveolar gas exchange and is largely occupying anatomic dead space.",
"   </p>",
"   <p>",
"    Pulsing devices are available as standalone modules or integrated into a liquid oxygen system, compressed gas system, or portable oxygen concentrator. A variety of protocols and formats are used to trigger, release and terminate oxygen delivery. Some devices are electronic with high precision settings while others are pneumatically controlled and driven. Settings for oxygen delivery are adjusted in some devices by varying the length of the oxygen pulse. Other devices deliver an early pulse each time they discharge, avoiding lengthening of the pulse into the dead space portion of inhalation. With this high efficiency of delivery, oxygen saturation can be maintained by delivery of a pulse on every other breath, leading to lower flow requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/13\">",
"     13",
"    </a>",
"    ]. Examples of pulsed oxygen delivery devices include the following: Chad-Oxymatic, Devilbiss-EX2000D, Helios, Invacare-Venture, Nellcor PB-CR50, Respironics e-POD, and Western O2 Advantage, among others.",
"   </p>",
"   <p>",
"    Demand devices vary in efficacy from 3:1 to 7:1, compared to continuous flow delivery. The batteries may last from three hours to one month, depending on the delivery protocol. Pneumatically driven units do not require batteries.",
"   </p>",
"   <p>",
"    Some devices have a feature in which they automatically revert to continuous flow if they fail to detect a breath in 20 to 30 seconds, but this feature uses more battery current.",
"   </p>",
"   <p>",
"    A potential problem with pulsing devices is that they may fail to adequately oxygenate some patients. This limitation can sometimes be prevented by modifying the device to deliver a larger pulse during the earliest part of inhalation or using a higher oxygen flow setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, oxygen conserving devices do not always perform as expected. In a study that compared four different oxygen conserving devices to continuous flow oxygen at 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    in patients with COPD, the devices varied in terms of the oxygen delivered, in the pulse oxygen saturation achieved, and in the exercise ability of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/17\">",
"     17",
"    </a>",
"    ]. Breath-by-breath output was variable for all devices in terms of activation of the pulse and the bolus size. Thus, it is always advisable to test each patient during rest and exertion to assure adequate saturation on the device being prescribed",
"   </p>",
"   <p>",
"    An innovation that may compensate for the difficulty with oxygenation during exercise is a device that senses the onset of activity and automatically increases oxygen delivery volume to a higher level to meet the patient's metabolic demands [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. The exercise delivery volume continues for 50 seconds following discontinuation of activity, and then reverts to the resting volume [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/18\">",
"     18",
"    </a>",
"    ]. These devices meet the patient's oxygen requirements during rest and exertion, and also conserve oxygen. An example of this device is the Sage",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Chad Therapeutics, Inc, Naples, FL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFICACY OF VARIOUS DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of these systems is expressed as the ratio of oxygen flow required by continuous flow delivery to the flow required by the conserver to achieve equivalent oxygen saturation.",
"   </p>",
"   <p>",
"    Efficacy = Continuous flow &nbsp;&divide; &nbsp;flow to conserving device (at equivalent saturation)",
"   </p>",
"   <p>",
"    The data presented in this section represent statistical means, and the actual equivalency may vary between patients. In addition, respiratory pattern, both respiratory rate and tidal volume, affect conserver efficiency. Thus, it is advisable to draw a blood gas or use non-invasive oximetry to determine the actual liter-flow setting prescription for the patient's various levels of rest and exertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reservoir systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of reservoir cannulas compared to continuous flow delivery is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef81603 \" href=\"UTD.htm?22/1/22557\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/6,7,19-22\">",
"     6,7,19-22",
"    </a>",
"    ]. Oxygen supplied at 0.5",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    via the reservoir cannulas achieves equivalent saturation to continuous flow at 2",
"    <span class=\"nowrap\">",
"     L/min.",
"    </span>",
"    Similarly, 1 and 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    reservoir settings are equivalent to 3 and 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    continuous flow, respectively. Thus, the efficacy of reservoir cannulas ranges between 2:1 and 4:1.",
"   </p>",
"   <p>",
"    For higher flows, reservoir cannulas add 2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    to continuous flow settings. For example, a reservoir cannula setting of 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    is equivalent to 6",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    by continuous flow. Studies performed during exercise and sleep generally yield results consistent with resting values, albeit with some variation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transtracheal systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of transtracheal oxygen delivery ranges between 2:1 and 3:1 over continuous flow delivery. Although the efficacy is reduced during exercise compared to rest [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/11,24\">",
"     11,24",
"    </a>",
"    ], patients generally have greater exercise tolerance and reduced work of breathing via transtracheal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=see_link\">",
"     \"Transtracheal oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Demand oxygen pulsing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of demand oxygen pulsing devices varies between 3:1 and 7:1 (",
"    <a class=\"graphic graphic_figure graphicRef73093 \" href=\"UTD.htm?27/2/27693\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/13,26-29\">",
"     13,26-29",
"    </a>",
"    ]. In general, this level of efficacy is maintained during exercise and sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/15,27-29\">",
"     15,27-29",
"    </a>",
"    ]. However, these measures reflect ideal performance and the efficacy of individual oxygen conserving devices may vary. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Demand oxygen pulsing devices'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pulsing oxygen through a transtracheal catheter maximizes the efficiency of oxygen delivery at 7:1 over continuous flow [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/14,30\">",
"     14,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lightweight compressed gas cylinders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total weight of an oxygen system consists of the cylinder, regulator and the oxygen conserving device. Composite cylinders are manufactured from aluminum liners and strengthened by carbon fiber in an epoxy resin matrix. These cylinders weight less than 50 percent of standard aluminum cylinders. They accept higher pressures up to 3000 psi and thus improve the portability of the portable oxygen system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liquid oxygen systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid oxygen does not require high pressure containers for oxygen storage; rather, a thermos like device called a Dewar Flask is used. One liquid liter of oxygen expands to nearly 1000 liters of gaseous oxygen deliverable to the patient. This has enabled the development of smaller and lighter systems that may be combined with an integrated pulse demand oxygen pulsing device or reservoir cannulas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Portable oxygen concentrators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable concentrators make use of improved battery technology and size and power of pumps and motors to provide battery-powered concentrators. Examples include Eclipse",
"    <sup>",
"     &reg;",
"    </sup>",
"    , EverGo",
"    <sup>",
"     &reg;",
"    </sup>",
"    , FreeStyle",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Inogen",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and XPO2",
"    <sup>",
"     &reg;",
"    </sup>",
"    with battery lives ranging from 2.5 to 8 hours.",
"   </p>",
"   <p>",
"    The weight and size of oxygen concentrators is partly determined by the flow requirement to the patient. Using an oxygen conserving device in conjunction with the concentrator enables adequate oxygen delivery at lower flows, thus relieving some of the limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients who use supplemental oxygen require an oxygen conserving device under all conditions. In general, an oxygen conserving device should be considered for patients who would benefit from a lower flow of oxygen or a lighter weight system. This would include patients who are ambulatory and wish to maintain an active lifestyle. Also, patients who live a long distance from their home medical equipment supplier should have a wider variety of options, as they must endure the practical limitation of less frequent home deliveries. The figure demonstrates the effect of oxygen conserving devices on extending cylinder life (",
"    <a class=\"graphic graphic_figure graphicRef59690 \" href=\"UTD.htm?11/11/11454\">",
"     figure 9",
"    </a>",
"    ). Patients with refractory hypoxemia may benefit from a reservoir cannula or transtracheal oxygen.",
"   </p>",
"   <p>",
"    Each conserving device has inherent advantages and drawbacks that should be evaluated by the clinician and patient. The choice between systems often requires compromise. The table compares the strengths and weakness of the different devices (",
"    <a class=\"graphic graphic_table graphicRef70691 \" href=\"UTD.htm?27/19/27963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some additional considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reservoir cannulas are the simplest, least expensive, and easiest for patients to convert from standard cannulas, but they may be obtrusive for some patients.",
"     </li>",
"     <li>",
"      Transtracheal oxygen delivery excels in cosmetics and may reduce the work of breathing, but it entails a minor surgical procedure, the catheter may form mucous balls at its tip, and it requires significant patient training.",
"     </li>",
"     <li>",
"      The demand devices are more efficient for both nasal and transtracheal delivery. These devices have enabled the development of integrative systems that maximize oxygen delivery. However, they make audible pulses that may be distracting and mechanical failure, albeit rare, is possible. Some pulsing devices fail to oxygenate patients adequately during exertion [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Economic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of long term oxygen therapy is significant and includes oxygen, equipment, and service to the home. In the United States, the Center of Medicare and Medicaid Services (CMS) has reported paying $2 billion for long term oxygen therapy. In 1989, CMS instituted a system of fixed reimbursement based on liter flow prescription for home oxygen. Since then, CMS has instituted several significant reductions in reimbursement for home oxygen. The profit margin for the home medical equipment (HME) suppliers can be maintained only by reducing their overhead. As a result, the HME supplier is economically driven to provide the least expensive system to purchase and maintain and the one that requires a minimum number of home service calls. Technologies aiding in this effort include: transtelephonic monitoring of oxygen concentrators, improved technologies to lengthen the life of concentrators, improved storage devices for liquid oxygen, conserving technologies and other innovations. However, in localities that have several competitive HME suppliers, those who supply patients with a more portable and ambulatory system may have a competitive advantage.",
"   </p>",
"   <p>",
"    Liquid oxygen offers the highest efficiency in oxygen storage, with safe and easy transfilling to the ambulatory unit. There are now oxygen conserving devices integrated into liquid oxygen flasks, which provide the smallest and most portable systems (weighing about 3.5 pounds). Liquid oxygen tends to be the most expensive system to purchase and maintain and some oxygen usually bleeds off to the atmosphere when the device is not in operation. Additionally, liquid oxygen systems may freeze up and thus, the patient needs to be educated about these problems and have backup plans established until oxygen delivery can be restored.",
"   </p>",
"   <p>",
"    Two integrated systems of oxygen concentrators that refill oxygen cylinders are available, Venture Home Fill",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Invacare Inc, Elyria, OH), and Total O2",
"    <sup>",
"     &reg;",
"    </sup>",
"    (CHAD Therapeutics Inc, Naples, FL). These systems obviate the necessity for home deliveries, which is the most costly aspect in providing domiciliary oxygen.",
"   </p>",
"   <p>",
"    The most commonly dispensed system for home use is an oxygen concentrator with a backup E cylinder designated to serve in the event of power failure or for infrequent portable use. Concentrators contain a synthetic aluminum silicate that traps and removes nitrogen molecules and thus yields a gas mixture of approximately 95 percent oxygen and 5 percent argon in the prescribed liter flow operating range [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21927/abstract/3\">",
"     3",
"    </a>",
"    ]. There are two basic concentrator systems: a low flow system (1 to 6",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    that will meet the oxygen delivery needs for most patients and a more expensive, high flow system (1 to 10",
"    <span class=\"nowrap\">",
"     L/min)",
"    </span>",
"    for patients with high oxygen requirements. In some hard to oxygenate patients, two concentrators in parallel may be used with success.",
"   </p>",
"   <p>",
"    Given the economic disincentive to supply liquid oxygen, some HME suppliers are considering alternatives. Oxygen conserving devices have expanded the delivery life of the smallest oxygen cylinders from one hour of continuous flow to seven hours of pulsed flow. Some of these compressed oxygen systems weigh less than 1.8 kg, comparing favorably to standard 4.3 kg liquid systems supplying a similar delivery life. Newer liquid oxygen systems have been developed that are lighter and more portable, owing to the integration of oxygen conserving devices. The Helios weighs 1.5 kg and lasts 10 hours between refills, thus providing the dual advantages of portability and transfillability. If a patient needs oxygen flow for more than 10 hours, access to a liquid oxygen reservoir to transfill their Helios system will be necessary.",
"   </p>",
"   <p>",
"    When considering the cost savings of oxygen conserving methodologies, the cost of the oxygen conserving device must be included. This actually happens in the marketplace, since the HME supplier must decide which equipment it will make available to patients. In addition, patients who require higher oxygen flows or have refractory hypoxemia would derive clinical benefit beyond convenience and portability, since the alternative may require the patient to tolerate hypoxemia.",
"   </p>",
"   <p>",
"    Several portable oxygen concentrators have been developed that are battery driven, weigh between 5 and 15 pounds, and are approved for patients to take on airlines. Most have an integrated conserver, but some larger units provide continuous flow oxygen delivery options.",
"   </p>",
"   <p>",
"    The Medicare system of reimbursement incorporates financial disincentives to using oxygen conserving devices. If the patient, as a result of requiring less oxygen, falls into a lower reimbursement category based on a lower prescribed liter flow, the HME supplier receives a reduced payment. With a device that is more expensive, this incentive seems backwards. Reservoir cannulas and transtracheal catheters are particularly affected by lower liter-flow settings, as opposed to the pulsing devices, whose settings (in absolute numbers) are intended to correspond to continuous flow settings, although they may not provide equivalent saturations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen conserving devices offer greater versatility, portability, and cost savings for patients using oxygen systems. They all involve tradeoffs on cost, weight, portability, cosmesis, availability, and efficiency (",
"      <a class=\"graphic graphic_table graphicRef70691 \" href=\"UTD.htm?27/19/27963\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Each patient who is considered for an oxygen conserving device should have arterial blood gases or oximetry tested using that device during wakeful rest, usual exercise, and perhaps during sleep to ensure an adequate oxygen prescription. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy of various devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients who are active away from their stationary system prefer to use a lightweight oxygen system combined with an oxygen pulsing device to maximize ease of portability and duration of oxygen supply. Oxygen conserving devices have enabled the development of light weight portable oxygen concentrators. However, portable oxygen concentrators may be limited by short battery life. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy of various devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require high flow oxygen (ie, 4",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      or greater), a reservoir device, either a moustache cannula or a reservoir pendant may be prescribed. Patients who do not require high flow oxygen, but who wish to prolong their oxygen supply by lowering the flow rate may also try a reservoir device. These may be worn both at rest and with activity, although comfort and cosmetic issues may limit use.(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Reservoir cannulas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As oxygen requirements increase (eg, in patients with idiopathic pulmonary fibrosis, pulmonary hypertension), demand oxygen pulsing devices may not achieve adequate arterial oxygenation, particularly during exertion. Continuous flow is then necessary, with the setting adjusted to achieve adequate saturations at rest and with exertion. Reservoir cannulas are also used to improve oxygen delivery without increasing the liter flow. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Demand oxygen pulsing devices'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Reservoir systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of oxygen conserving devices has led to innovations such as portable oxygen concentrators, oxygen concentrators that refill portable cylinders, and activity adaptive oxygen delivery devices. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Efficacy of various devices'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/1\">",
"      McCoy R. Oxygen-conserving techniques and devices. Respir Care 2000; 45:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/2\">",
"      Keller RR. Long-term oxygen therapy: advances and perspectives in technical devices. Monaldi Arch Chest Dis 1999; 54:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/3\">",
"      Rees PJ, Dudley F. Provision of oxygen at home. BMJ 1998; 317:935.",
"     </a>",
"    </li>",
"    <li>",
"     Tiep BL. Continuous flow oxygen therapy and basis for improving the efficiency of oxygen delivery. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York 1991. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/5\">",
"      Mithoefer JC, Keighley JF, Karetzky MS. Response of the arterial Po2 to oxygen administration in chronic pulmonary disease. Interpretation of findings in a study of 46 patients and 14 normal subjects. Ann Intern Med 1971; 74:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/6\">",
"      Soffer M, Tashkin DP, Shapiro BJ, et al. Conservation of oxygen supply using a reservoir nasal cannula in hypoxemic patients at rest and during exercise. Chest 1985; 88:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/7\">",
"      Gonzales, S, Huntington, D, Remo, R, Light, R. Efficacy of the Oxymizer Pendant in reducing oxygen requirements of hypoxemic patients. Respir Care 1986; 31:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/8\">",
"      Collard P, Wautelet F, Delwiche JP, et al. Improvement of oxygen delivery in severe hypoxaemia by a reservoir cannula. Eur Respir J 1989; 2:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/9\">",
"      Sheehan, JC, O'Donohue, WJ. Use of a reservoir nasal cannula in hospitalized patients with refractory hypoxemia. Chest 1996; 110:s1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/10\">",
"      Heimlich HJ. Respiratory rehabilitation with transtracheal oxygen system. Ann Otol Rhinol Laryngol 1982; 91:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/11\">",
"      Christopher KL, Spofford BT, Petrun MD, et al. A program for transtracheal oxygen delivery. Assessment of safety and efficacy. Ann Intern Med 1987; 107:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/12\">",
"      Christopher KL, Spofford BT, Brannin PK, Petty TL. Transtracheal oxygen therapy for refractory hypoxemia. JAMA 1986; 256:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/13\">",
"      Tiep BL, Nicotra MB, Carter R, et al. Low-concentration oxygen therapy via a demand oxygen delivery system. Chest 1985; 87:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/14\">",
"      Tiep BL, Christopher KL, Spofford BT, et al. Pulsed nasal and transtracheal oxygen delivery. Chest 1990; 97:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/15\">",
"      Fuhrman C, Chouaid C, Herigault R, et al. Comparison of four demand oxygen delivery systems at rest and during exercise for chronic obstructive pulmonary disease. Respir Med 2004; 98:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/16\">",
"      Tiep BL, Barnett J, Schiffman G, et al. Maintaining oxygenation via demand oxygen delivery during rest and exercise. Respir Care 2002; 47:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/17\">",
"      Palwai A, Skowronski M, Coreno A, et al. Critical comparisons of the clinical performance of oxygen-conserving devices. Am J Respir Crit Care Med 2010; 181:1061.",
"     </a>",
"    </li>",
"    <li>",
"     Tiep, BL, Murray, R, Barnett, M, Carter, R. Auto-adjusting demand oxygen delivery system that minimizes SaO2 swings between rest and exertion. Chest 2004 (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/19\">",
"      Tiep BL, Nicotra B, Carter R, et al. Evaluation of a low-flow oxygen-conserving nasal cannula. Am Rev Respir Dis 1984; 130:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/20\">",
"      Pesce, L, Lauro, S, Testi, R, et al. Effetti della somministrazione de ossigeno attraverso un nuovo dispositivo economizzatore in 20 pazienti affetti da insufficcienza respiratoria. Min Pneum 1987; 25:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/21\">",
"      Carter R, Williams JS, Berry J, et al. Evaluation of the pendant oxygen-conserving nasal cannula during exercise. Chest 1986; 89:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/22\">",
"      Hagarty EM, Skorodin MS, Stiers WM, et al. Performance of a reservoir nasal cannula (Oxymizer) during sleep in hypoxemic patients with COPD. Chest 1993; 103:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/23\">",
"      Cuvelier A, Muir JF, Czernichow P, et al. Nocturnal efficiency and tolerance of a demand oxygen delivery system in COPD patients with nocturnal hypoxemia. Chest 1999; 116:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/24\">",
"      Hoffman LA, Wesmiller SW, Sciurba FC, et al. Nasal cannula and transtracheal oxygen delivery. A comparison of patient response after 6 months of each technique. Am Rev Respir Dis 1992; 145:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/25\">",
"      Benditt J, Pollock M, Roa J, Celli B. Transtracheal delivery of gas decreases the oxygen cost of breathing. Am Rev Respir Dis 1993; 147:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/26\">",
"      Garrod R, Bestall JC, Paul E, Wedzicha JA. Evaluation of pulsed dose oxygen delivery during exercise in patients with severe chronic obstructive pulmonary disease. Thorax 1999; 54:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/27\">",
"      Carter R, Tashkin D, Djahed B, et al. Demand oxygen delivery for patients with restrictive lung disease. Chest 1989; 96:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/28\">",
"      Franco, MA, Conner, SA, Gougenheim, C. Pulse dose oxygen delivery during exercise. Respir Care 1985; 30:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/29\">",
"      Bower JS, Brook CJ, Zimmer K, Davis D. Performance of a demand oxygen saver system during rest, exercise, and sleep in hypoxemic patients. Chest 1988; 94:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21927/abstract/30\">",
"      Yaeger ES, Goodman S, Hoddes E, Christopher KL. Oxygen therapy using pulse and continuous flow with a transtracheal catheter and a nasal cannula. Chest 1994; 106:854.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1442 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21927=[""].join("\n");
var outline_f21_26_21927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONTINUOUS FLOW NASAL CANNULA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPES OF OXYGEN CONSERVING DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reservoir cannulas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transtracheal catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Demand oxygen pulsing devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFICACY OF VARIOUS DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reservoir systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transtracheal systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Demand oxygen pulsing devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lightweight compressed gas cylinders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liquid oxygen systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Portable oxygen concentrators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Economic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1442|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4830\" title=\"figure 1\">",
"      Oxygen flow rate and FiO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/30/26081\" title=\"figure 2\">",
"      Use of nasal reservoir cannula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/42/3744\" title=\"figure 3\">",
"      Demand pulsed oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/40/26254\" title=\"figure 4\">",
"      Oxygen delivery in inspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4688\" title=\"figure 5\">",
"      Model of inspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/30/8685\" title=\"figure 6\">",
"      Pulsed nasal O2 delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/1/22557\" title=\"figure 7\">",
"      Reservoir cannulas and SaO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/2/27693\" title=\"figure 8\">",
"      Pulse demand device and SaO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/11/11454\" title=\"figure 9\">",
"      Extended cylinder life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/19/27963\" title=\"table 1\">",
"      Comparison O2 conserv devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/20/11595\" title=\"table 2\">",
"      Benefits transtracheal O2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?34/7/34928?source=related_link\" title=\"calculator 1\">",
"      Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=related_link\">",
"      Transtracheal oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21928="Immune thrombocytopenia - ITP";
var content_f21_26_21928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76671%7EDERM%2F70793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76671%7EDERM%2F70793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Immune thrombocytopenia (ITP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Petechiae are present on the legs of this patient with immune thrombocytopenia (ITP).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar purpura",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple purpuric patches are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21928=[""].join("\n");
var outline_f21_26_21928=null;
var title_f21_26_21929="Placental pathology in cases of neurologically impaired infants";
var content_f21_26_21929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placental pathology in cases of neurologically impaired infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Raymond W Redline, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21929/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/26/21929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) and related causes of long-term neurologic impairment occur in approximately 2.0 to 2.5 per 1000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Over 50 percent of affected children were born at term (37 weeks of gestation or more), 25 to 40 percent were delivered prior to 32 weeks of gestation, and the remainder were born between 32 and 37 weeks of gestation.",
"   </p>",
"   <p>",
"    In population-based studies, risk factors for delivery of a neurologically impaired child include maternal infection, placental infection (acute chorioamnionitis), intrauterine growth restriction, and a family history of CP or related neurologic disorders. Immaturity and malformations of the central nervous system (CNS) are common causes of neurologic impairment among children delivered preterm. By comparison, few neurologically impaired children born at term have a clearly identifiable etiologic factor. Causes include perinatal stroke, an inborn error of metabolism (eg, mitochondrial disorders), CNS infection, congenital hypothyroidism, and exposure to an exogenous (eg, mercury) or endogenous (eg, bilirubin) toxin.",
"   </p>",
"   <p>",
"    The contribution of intrapartum hypoxia to neural injury in term infants is controversial. In the United States and other developed countries the large number of medical liability claims against physicians who delivered neurologically impaired children has led to a crisis that threatens the availability of obstetrical care [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiologic studies suggest that intrapartum hypoxia is a direct cause of only about 9 percent of cases of CP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other evidence suggests that most CNS injury occurs in the intrapartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/7\">",
"     7",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics have proposed essential criteria needed to define that an acute intrapartum event was sufficient to cause cerebral palsy, as well as the collective criteria that suggest intrapartum timing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placental pathology can identify clinically silent, pathophysiologic processes that can directly cause CNS damage, decrease the threshold for neurological injury, or serve as markers for a deleterious in utero environment. Placental lesions associated with neurodisability have been found in the placentas of infants at all birth weights, but are most helpful for understanding unanticipated poor outcomes in term infants. This topic will review the association of findings on placental examination and adverse neurologic outcome in very low birth weight infants, followed by a more detailed consideration of the categories and specific placental findings found in the placentas of term infants with long-term neurologic impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PLACENTAL LESIONS IN PRETERM DELIVERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS damage related to immaturity of the developing brain and cardiopulmonary system is the major cause of CP and other long-term neurologic deficits in very low birth weight (VLBW, &lt;1.5 kg) and extremely low birth weight (ELBW, &lt;1.0 kg) infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. While placental lesions may modulate the risk, they are usually not the sole factor causing brain injury in these infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology and etiology of cerebral palsy\", section on 'Prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal vasculitis and histological chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis analyzing chorioamnionitis as a risk factor for CP found a significant association between clinical chorioamnionitis and CP in premature infants (RR 1.9, 95% CI 1.4-2.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/11\">",
"     11",
"    </a>",
"    ]. The relationship between histological chorioamnionitis (HCA) to this outcome was not statistically significant (RR 1.6, 95% CI 0.9-2.7).",
"   </p>",
"   <p>",
"    However, there appears to be a significant association between acute fetal vasculitis (which commonly accompanies HCA in preterm placentas) and sonographically-defined white matter lesions in VLBW and ELBW newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The association between acute fetal vasculitis and development of CP-related neurological processes in older children is less clear. In one study of VLBW infants, there was a weak association between HCA and development of CP-related forms of neurologic impairment when HCA was accompanied by high grade acute fetal vasculitis or acute fetal vasculitis with chorionic vessel thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/14\">",
"     14",
"    </a>",
"    ]. Another study of ELBW infants failed to find any association of HCA or acute fetal vasculitis with either CP or abnormal neurocognitive testing in the group as a whole, but did find that high grade acute fetal vasculitis predicted lower neurocognitive test scores in the subgroup with HCA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between acute fetal vasculitis and CNS lesions supports the hypothesis that increased circulating cytokines may damage immature oligodendroglia in the developing CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This theory is supported by studies showing that cytokine levels are higher when vasculitis affects the umbilical artery or arteries, as opposed to the umbilical vein",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chorionic plate vessels alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paradoxically, a few reports have found that placentas with HCA are associated with improved survival and better short-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This may be due, in part, to the powerful deleterious effects of other pathologic lesions associated with preterm birth, such as severe maternal vascular disease and villous edema (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Severe maternal vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large studies have demonstrated an increased prevalence of CP and other neurodevelopmental disorders in small for gestational age infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Maternal vascular disease secondary to abnormal arterial remodeling in early pregnancy is the most common cause of growth restriction in preterm infants and, when severe, can be associated with abnormal fetal blood flow in several vascular beds, including the middle cerebral artery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autopsy studies have shown a significant relationship between maternal vascular lesions in the placenta (infarcts and increased syncytial knots) and neuronal necrosis in stillbirths [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. A study of ELBW infants found that placental lesions (increased syncytial knots, multiple villous infarcts, decidual arteriopathy [acute atherosis]) associated with maternal vascular disease were strongly associated with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/15\">",
"     15",
"    </a>",
"    ]. A previous study in VLBW infants had suggested a biphasic relationship, with less severe lesions correlating with better outcomes and more severe lesions correlating with worse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, a population-based study of placental infarcts identified by gross inspection of the placenta in singleton pregnancies &gt;35 weeks gestational age found a two-fold increase in CP and an eight-fold increase in CP with spastic quadriplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/29\">",
"     29",
"    </a>",
"    ]. Although handicapped by lack of histologic confirmation, this study suggests that placental infarction should be separated from other signs of maternal malperfusion in all future studies of the placenta and neurodisability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Villous edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surprising finding reported several decades ago was that diffuse multifocal edema affecting the immature intermediate villi of preterm placentas (villous edema) was strongly associated with low Apgar scores and an increased risk of acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/30\">",
"     30",
"    </a>",
"    ]. Subsequent studies have shown that this lesion is also associated with an increased risk of neonatal death, CP, and chronic lung disease in VLBW infants, and lower neurocognitive scores at school age in ELBW infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/15,26,31,32\">",
"     15,26,31,32",
"    </a>",
"    ]. Analysis of the data in the latter study showed three distinct pathologic subgroups: infants with placental maternal vascular lesions who had an increased incidence of CP, infants with placental villous edema who had lower neurocognitive test scores, and infants with neither who had the lowest rates of both adverse outcomes. Infants with placental maternal vascular lesions rarely had HCA, while those in the latter two groups had equivalent high rates of HCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Multiple placental lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants have a dramatically enhanced risk of neurodisability when the placenta has more than one lesion associated with adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. These lesions include all of the aforementioned lesions, plus longstanding chorioamnionitis with amnion necrosis (necrotizing chorioamnionitis), retroplacental hematomas with intraplacental extension (findings consistent with abruption placenta), and increased circulating nucleated red blood cells (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that the risk of CP and neurodisability is increased in multiple gestations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/34\">",
"     34",
"    </a>",
"    ]. This risk is greatest in pathologically confirmed, monochorionic twin placentas. The suggestion that increased risk, at least in part, relates to episodes of circulatory imbalance with transient hypotension in one or both twins is supported by the very high prevalence of CNS lesions following fetal demise of one twin in pregnancies with monochorionic placentas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/35\">",
"     35",
"    </a>",
"    ] and in twin-twin transfusion syndrome. No studies have systematically evaluated other placental lesions that might increase the risk of neurodisability in multiple gestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H24#H24\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Death of one twin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PLACENTAL LESIONS IN TERM DELIVERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying clinical risk factors explaining CNS injury in term infants are less well-defined than in premature infants. Placental pathology can identify processes that directly contribute to neurologic impairment, and can also identify placentas with decreased functional reserve and adaptive changes indicative of an abnormal intrauterine environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Processes associated with fetal hypoxia occurring less than four to six hours prior to delivery are generally only detectable by pathologic examination of the placenta if they result in disruption and deformation of placental tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Abruptio placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the diagnosis of abruptio placenta is made clinically. However, direct visualization of a large central retroplacental blood clot with indentation of the placenta or rupture of the basal plate at the time of cesarean delivery is strong evidence of abruptio placentae (",
"    <a class=\"graphic graphic_picture graphicRef60258 \" href=\"UTD.htm?37/23/38258\">",
"     picture 1",
"    </a>",
"    ). Sonographic diagnosis, clinical signs and symptoms, and histological findings (diffuse retromembranous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intradecidual hemorrhages, irregular basal intervillous thrombi, and recent villous stromal hemorrhage) are less specific for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Complete umbilical cord occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Processes associated with acute total or near-total obstruction of umbilical blood flow include tight knot, cord prolapse, and severe torsion related to cord entanglements or",
"    <span class=\"nowrap\">",
"     marginal/membranous",
"    </span>",
"    cord insertion (",
"    <a class=\"graphic graphic_picture graphicRef51778 \" href=\"UTD.htm?20/28/20933\">",
"     picture 2",
"    </a>",
"    ). Pathologic findings supporting these scenarios include distinct differences in cord diameter, color, and vascular congestion on either side of the putatively obstructed area and dilatation of large vessels in the chorionic plate and primary stem villi.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fetal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum fetal hemorrhages occur due to placental vascular disruptions, most commonly involving the tearing of unsupported fetal vessels in the membranes (ruptured vasa previa). A rare type of catastrophic fetal hemorrhage involves subamnionic and umbilical cord hematomas caused by extreme stretching of an entangled umbilical cord during fetal descent through the birth canal. All of these types of fetal hemorrhage occur quite commonly after delivery of the infant in the third stage of labor, therefore, evidence of spread of hemorrhage into adjacent tissues and blood loss in the neonate are necessary before imparting significance to any of these placental findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Subacute processes (partial prolonged hypoxia)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of partial prolonged hypoxia was originally introduced by investigators working with primate models of birth asphyxia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/37\">",
"     37",
"    </a>",
"    ]. This concept has been utilized by neurologists and neuroradiologists to describe specific patterns of brain injury related to sustained or repetitive periods of significant hypoxia or other systemic stress affecting the fetus over a period of many hours to days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     HCA and severe acute fetal vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis evaluating the association between chorioamnionitis and CP in term and late preterm infants found that clinical signs of chorioamnionitis were a significant risk factor for CP in these infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/39\">",
"     39",
"    </a>",
"    ]. However, HCA is a common placental lesion, affecting between 10 to 15 percent of placentas delivered at term, while CP is rare. A few studies have evaluated subtypes of HCA that might be stronger risk factors for development of brain injury. High grade acute fetal vasculitis, defined by confluent neutrophilic infiltration of chorionic or umbilical vessel walls plus disorganization of vascular smooth muscle fibers and endothelial activation, has been identified as a highly significant risk factor for CP and related forms of neurodisability. All other grades and stages of HCA studied were equally prevalent in the placentas of term infants with and without neurologic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Meconium exposure with fetal vascular necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meconium stained amniotic fluid is noted in 10 to 15 percent of term births. While the prevalence is somewhat higher in the placentas of infants with neurologic impairment, there is no significant association between meconium histiocytosis in the amnion or chorionic plate and adverse outcome.",
"   </p>",
"   <p>",
"    Meconium-associated necrosis of vascular smooth muscle cells in the chorionic or umbilical vessels is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. This lesion has been associated with prolonged meconium exposure, and may develop due to toxic effects of bile acids and other constituents of meconium. Meconium-associated vascular necrosis is much more common in the placentas of term infants with neurologic impairment and is a highly significant risk factor for this outcome (",
"    <a class=\"graphic graphic_picture graphicRef67487 \" href=\"UTD.htm?25/32/26117\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link&amp;anchor=H5#H5\">",
"     \"Histopathology of placental disorders\", section on 'Meconium stained cord'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic intermittent umbilical cord occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic intermittent umbilical cord occlusion is difficult to diagnose clinically and hard to confirm by pathologic examination. Studies in which serial ultrasound examinations were utilized in late gestation have linked this process with abnormal neurologic outcome at one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placental findings suggestive of chronic intermittent umbilical cord occlusion include intimal fibrin cushions representing either insudation of fibrin or deposition of extracellular matrix in the walls of large fetal vessels, dilatation of large primary stem villous vessels, and scattered small foci of degenerating terminal villi indicative of decreased fetal perfusion in the most distal portions of the fetoplacental circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. More severe umbilical cord occlusion can cause more extensive areas of stromal vascular karyorrhexis in the distal villous tree, a process also known as hemorrhagic endovasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/47\">",
"     47",
"    </a>",
"    ]. Many of these cases also show an increase in circulating nucleated red blood cells (NRBC) (see below), indicative of significant fetal hypoxemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Subacute abruption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute abruption is characterized by an episode or episodes of placental abruption not leading to immediate delivery. The pathologic findings in cases of subacute abruption are an organizing retroplacental hematoma with overlying recent villous infarction. Recent infarcts are characterized by preservation of villous stromal architecture, eosinophilic degeneration of the syncytiotrophoblast, and villous agglutination with scattered intervillous neutrophils. These infarcts take approximately four to six hours to develop.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive fetal hemorrhage into the maternal circulation is a rare, but important cause of unexpected adverse outcomes. Clinically it may be accompanied by decreased fetal movement and a sinusoidal fetal heart rate pattern. A positive Kleihauer-Betke or flow cytometric test identifying fetal RBC in the maternal circulation is the standard test used for diagnosis, but is often not requested by health care providers. In other cases, these tests may be falsely negative because of ABO incompatibility resulting in rapid lysis of fetal cells.",
"   </p>",
"   <p>",
"    Placental findings of a marked increase in circulating NRBC within villous capillaries plus large or multiple intervillous thrombi in the placenta are suggestive of the diagnosis of fetomaternal hemorrhage, particularly when accompanied by a low neonatal hematocrit and a sustained increase in the NRBC count in the first few days following birth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link&amp;anchor=H25#H25\">",
"     \"Histopathology of placental disorders\", section on 'Intervillous thrombi'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Active chronic placental disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active, chronic placental disease processes have their onset weeks prior to delivery and are progressive, continuing to cause deterioration of placental function at an unpredictable rate until delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Fetal thrombotic vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal thrombotic vasculopathy is characterized by multiple foci of devascularized distal villi, in varying stages of degeneration, usually accompanied by identifiable organizing thrombi in upstream feeding vessels in the chorionic plate or large stem villi (",
"    <a class=\"graphic graphic_picture graphicRef59894 \" href=\"UTD.htm?11/51/12087\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/50\">",
"     50",
"    </a>",
"    ]. This placental lesion is closely related to the condition known as \"hemorrhagic endovasculitis\" (",
"    <a class=\"graphic graphic_picture graphicRef50997 \" href=\"UTD.htm?31/19/32056\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]. The total number of degenerating villi required for diagnosis must exceed an average of 15 per parenchymal section [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/52\">",
"     52",
"    </a>",
"    ]. Depending on the duration of upstream vascular occlusion, distal villi either show stromal-vascular karyorrhexis (&gt;24 hours) or become totally avascular and hyalinized (&gt;7 days). Usually the latter predominate.",
"   </p>",
"   <p>",
"    Fetal thrombotic vasculopathy has been strongly associated with neonatal encephalopathy, CP, and other related forms of neurologic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/41,53-56\">",
"     41,53-56",
"    </a>",
"    ]. Etiologies include pathologic abnormalities of the umbilical cord, cord entanglements, fetal thrombophilia, maternal antiphospholipid syndrome, and maternal diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/50,57-59\">",
"     50,57-59",
"    </a>",
"    ]. This condition can potentially cause brain injury either directly via embolization of placental clots through the umbilical vein to the middle cerebral artery via the ductus venosus and foramen ovale, or indirectly secondary to a fetal coagulopathy, sometimes accompanied by thrombocytopenia and thrombi in other fetal organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chronic villitis with obliterative fetal vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic villitis (also known as villitis of unknown etiology) is a relatively common chronic inflammatory disorder (5 to 10 percent of term placentas), usually affecting only the distal chorionic villi (",
"    <a class=\"graphic graphic_picture graphicRef64413 \" href=\"UTD.htm?37/4/37958\">",
"     picture 6",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef77237 \" href=\"UTD.htm?41/50/42793\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The inflammatory infiltrate is primarily composed of maternal T lymphocytes and this condition may represent a maternal host versus graft reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/62\">",
"     62",
"    </a>",
"    ]. In rare cases, inflammatory cells extend into more proximal villi and the chorionic plate where they can cause an obliterative fetal vasculopathy characterized by chronic vasculitis, luminal narrowing, and thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/52\">",
"     52",
"    </a>",
"    ]. Downstream villi show a combination of inflammation and the degenerative changes described above for fetal thrombotic vasculopathy. Chronic villitis alone has been associated with fetal growth restriction and recurrent reproductive loss. When accompanied by obliterative fetal vasculopathy, it has been strongly associated with CP and related neurologic impairment in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Massive perivillous fibrin deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive perivillous fibrin deposition (\"maternal floor infarction\") is a rare idiopathic placental disease process characterized by progressive obliteration of the intervillous space by a combination of fibrin and fibrinoid extracellular matrix material (",
"    <a class=\"graphic graphic_picture graphicRef59608 \" href=\"UTD.htm?15/17/15637\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/63\">",
"     63",
"    </a>",
"    ]. The etiology is unclear, with some studies suggesting an association with autoimmune disease, maternal thrombophilia, and hypertensive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. It is often recurrent and can cause a variety of adverse outcomes including spontaneous abortion, premature delivery, fetal demise, and severe fetal growth restriction. One study showed a significant increase in adverse neurodevelopmental outcomes in infants born with placentas showing this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/67\">",
"     67",
"    </a>",
"    ]. Another study reported a significant association with CP and related neurologic conditions in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chronic peripheral placental separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic peripheral placental separation is the pathologic correlate of the chronic abruption-oligohydramnios sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. It is characterized clinically by repetitive episodes of vaginal bleeding, often in all trimesters of pregnancy. Sonographic evidence of so-called subchorionic hemorrhages may be detected in some cases. Pathologically, chronic peripheral separation is characterized by circumvallate membrane insertion, old degenerating marginal blood clots,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diffuse hemosiderosis of the placental membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/70\">",
"     70",
"    </a>",
"    ]. It is a recognized cause of premature delivery and affected infants show a specific pattern of lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/71\">",
"     71",
"    </a>",
"    ]. It has not been associated with neurologic impairment in preterm infants. A clinical diagnosis of chronic vaginal bleeding was found to be a significant risk factor for CP in the Collaborative Perinatal Project study conducted in the 1960s and membrane hemosiderin deposition was an independent predictor of CP and related neurologic disorders in a study of term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40,72\">",
"     40,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Chronic placental insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that the placenta has an approximately 30 percent reserve capacity to maintain maternofetal gas exchange during times of stress. Conditions that reduce reserve by decreasing the volume or efficiency of placental tissue do not directly cause brain injury, but can decrease the ability of the fetoplacental unit to withstand significant stresses that occur during the course of normal labor and delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Maternal underperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic findings indicative of relative maternal underperfusion (also known as uteroplacental insufficiency) are common, affecting 10 to 20 percent of all deliveries. These findings are indicative of inadequate spiral arterial flow, generally due to abnormal trophoblast-dependent remodeling during the early stages of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/73\">",
"     73",
"    </a>",
"    ]. Clinical conditions associated with maternal underperfusion include pregnancy-related hypertension, fetal growth restriction, oligohydramnios, and abnormal pulsed flow Doppler studies.",
"   </p>",
"   <p>",
"    Associated pathologic findings include decreased placental weight, increased fetoplacental weight ratio, increased syncytial knots and intervillous fibrin (affecting &gt;30 percent of total sampled parenchyma), distal villous hypoplasia, a thin umbilical cord, villous infarcts (",
"    <a class=\"graphic graphic_picture graphicRef51550 \" href=\"UTD.htm?36/62/37865\">",
"     picture 9",
"    </a>",
"    ), laminar decidual necrosis, and spiral artery abnormalities including acute atherosis, mural hypertrophy, and luminal",
"    <span class=\"nowrap\">",
"     thrombosis/fibrous",
"    </span>",
"    obliteration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. While these changes are all suggestive of decreased placental reserve, by themselves none are associated with CP or related neurologic abnormalities in term infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Macrosomia, placentomegaly, distal villous immaturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic changes associated with excessive levels of fetal insulin or other fetoplacental growth factors may be seen in pregnancies complicated by maternal diabetes, obesity, excessive weight gain, and fetal Beckwith-Wiedemann Syndrome. These pathologic changes include placentomegaly (weight greater than 90th percentile for gestational age) and distal villous immaturity (increased villous stroma and decreased vasculosyncytial membranes) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of excessive demand due to increased fetoplacental mass and inefficient villous gas exchange due to villous immaturity decreases placental reserve and has been associated with stillbirth and other perinatal complications. While these changes may impair the placental capacity to withstand stress, no direct evidence of a link to CP and related neurologic conditions has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Stressful intrauterine environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus and placenta undergo a number of adaptive changes triggered by persisting alterations in the delivery of critical substrates from the maternal circulation. Unlike the changes described above, they are indicators of intrauterine status, not causes of placental insufficiency. In theory, these adaptations could improve placental function, but there is no evidence that they do so.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Increased circulating nucleated red blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure of the bone marrow and other sites of fetal hematopoiesis (eg, liver) to persistent and significantly decreased levels of oxygen results in the release of erythropoietin (via hypoxia inducible factor-1, HIF-1 alpha) which stimulates increased production and premature release of NRBC (RBC precursors) into the peripheral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/78\">",
"     78",
"    </a>",
"    ]. The ability to detect increased circulating NRBC in placental sections corresponds to a level of approximately",
"    <span class=\"nowrap\">",
"     2500/mm3",
"    </span>",
"    in the neonatal peripheral blood count.",
"   </p>",
"   <p>",
"    Widely divergent estimates of the time required to detect such an increase in the level of NRBC (2 to 48 hours) have been reported; however, in vivo animal experiments agree with the clinical experience of many placental pathologists that it takes between 6 and 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/79\">",
"     79",
"    </a>",
"    ]. Higher levels of NRBC",
"    <span class=\"nowrap\">",
"     (&gt;10,000/mm3)",
"    </span>",
"    and prolonged elevations lasting several days after birth probably take 24 to 48 hours or longer to attain, but this estimate is not based on any experimental data.",
"   </p>",
"   <p>",
"    Causes of fetal hypoxemia associated with increased NRBC include both decreased oxygen tension and decreased oxygen delivery due to anemia (eg, blood group incompatibility or fetomaternal hemorrhage). It is important to stress that while significantly associated with CP and related neurologic disorders, increased NRBC are not causally related to them [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Villous chorangiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Villous chorangiosis is characterized by an increased number of capillaries observed in cross sections of distal villi probably reflect increased angiogenesis in the third trimester (",
"    <a class=\"graphic graphic_picture graphicRef80543 \" href=\"UTD.htm?29/34/30248\">",
"     picture 10",
"    </a>",
"    ). The classic definition of this lesion is more than 10 capillaries in more than 10 villi in several areas of the placenta, but most cases have far more than 10 capillaries in some villi [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Several reported associations support the hypothesis that this placental finding is a chronic adaptive change to decreased oxygen delivery, possibly triggered by VEGF-1 (vascular endothelial growth factor) - another HIF-1 alpha inducible gene. These associations include high altitude, maternal anemia, and heavy smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Unlike increased NRBC, there are no experimental data linking this adaptive change to CP and related conditions. Some data suggest that it is equally common in placentas submitted for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Multiple placental lesions (preconditioning)",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report examined the effects of having more than one significant placental risk factor for CP and related neurologic conditions in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/40\">",
"     40",
"    </a>",
"    ]. It was shown that multiple lesions acted synergistically and that each additional lesion significantly elevated the specificity of abnormal pathology for predicting adverse outcome. It was also found that lesions occurring at different time periods (eg, subacute superimposed on active chronic) were more strongly associated with outcome than lesions occurring at the same time. This sensitization or preconditioning might reflect the effects of later lesions on compensatory mechanisms invoked by the initial process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Placental pathology can identify a number of conditions with specific relationships to development of CP and related neurological disorders in children. While necessarily indirect, these findings can provide important insights into adverse antenatal environments that can impact susceptibility to brain injury. In order to ensure that these valuable data are factored into an analysis of the cause of brain injury in an infant, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Submit placenta to the Pathology Department according to recommendations developed by the College of American Pathologists [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=see_link\">",
"       \"Gross examination of the placenta\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It may also be necessary to discuss clinical findings and impressions with the Pathology Department to ensure that placentas are appropriately examined and sampled according to accepted guidelines so that important placental lesions are not missed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21929/abstract/86,87\">",
"       86,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consult a perinatal pathologist with experience in evaluating cases of adverse neurologic outcomes in cases subject to litigation. Consultation with such an expert is also suggested to identify placental lesions and explain their significance to the family early after problem deliveries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research exploring the relationship of placental lesions, biomarkers, and specific genetic variations to adverse outcomes is needed.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/1\">",
"      Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. Multivariate analysis of risk. N Engl J Med 1986; 315:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/2\">",
"      Pharoah PO, Platt MJ, Cooke T. The changing epidemiology of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 1996; 75:F169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/3\">",
"      Himmelmann K, Hagberg G, Beckung E, et al. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr 2005; 94:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/4\">",
"      MacLennan A, Nelson KB, Hankins G, Speer M. Who will deliver our grandchildren? Implications of cerebral palsy litigation. JAMA 2005; 294:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/5\">",
"      Blair E, Stanley FJ. Intrapartum asphyxia: a rare cause of cerebral palsy. J Pediatr 1988; 112:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/6\">",
"      Freeman JM, Nelson KB. Intrapartum asphyxia and cerebral palsy. Pediatrics 1988; 82:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/7\">",
"      Cowan F, Rutherford M, Groenendaal F, et al. Origin and timing of brain lesions in term infants with neonatal encephalopathy. Lancet 2003; 361:736.",
"     </a>",
"    </li>",
"    <li>",
"     Neonatal encephalopathy and cerebral palsy: defining the pathogenesis and pathophysiology. American College of Obstetricians and Gynecologists and American Academy of Pediatrics, Washington DC, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/9\">",
"      Murphy DJ, Hope PL, Johnson A. Neonatal risk factors for cerebral palsy in very preterm babies: case-control study. BMJ 1997; 314:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/10\">",
"      Wilson-Costello D, Borawski E, Friedman H, et al. Perinatal correlates of cerebral palsy and other neurologic impairment among very low birth weight children. Pediatrics 1998; 102:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/11\">",
"      Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000; 284:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/12\">",
"      Bejar R, Wozniak P, Allard M, et al. Antenatal origin of neurologic damage in newborn infants. I. Preterm infants. Am J Obstet Gynecol 1988; 159:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/13\">",
"      Leviton A, Paneth N, Reuss ML, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res 1999; 46:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/14\">",
"      Redline RW, Wilson-Costello D, Borawski E, et al. Placental lesions associated with neurologic impairment and cerebral palsy in very low-birth-weight infants. Arch Pathol Lab Med 1998; 122:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/15\">",
"      Redline RW, Minich N, Taylor HG, Hack M. Placental lesions as predictors of cerebral palsy and abnormal neurocognitive function at school age in extremely low birth weight infants (&lt;1 kg). Pediatr Dev Pathol 2007; 10:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/16\">",
"      Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/17\">",
"      Dammann O, Allred EN, Leviton A, et al. Fetal vasculitis in preterm newborns: interrelationships, modifiers, and antecedents. Placenta 2004; 25:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/18\">",
"      Kim CJ, Yoon BH, Romero R, et al. Umbilical arteritis and phlebitis mark different stages of the fetal inflammatory response. Am J Obstet Gynecol 2001; 185:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/19\">",
"      Rogers BB, Alexander JM, Head J, et al. Umbilical vein interleukin-6 levels correlate with the severity of placental inflammation and gestational age. Hum Pathol 2002; 33:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/20\">",
"      Lahra MM, Jeffery HE. A fetal response to chorioamnionitis is associated with early survival after preterm birth. Am J Obstet Gynecol 2004; 190:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/21\">",
"      Richardson BS, Wakim E, daSilva O, Walton J. Preterm histologic chorioamnionitis: impact on cord gas and pH values and neonatal outcome. Am J Obstet Gynecol 2006; 195:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/22\">",
"      Jarvis S, Glinianaia SV, Torrioli MG, et al. Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 2003; 362:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/23\">",
"      Bergvall N, Iliadou A, Johansson S, et al. Risks for low intellectual performance related to being born small for gestational age are modified by gestational age. Pediatrics 2006; 117:e460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/24\">",
"      Hansen AR, Collins MH, Genest D, et al. Very low birthweight placenta: clustering of morphologic characteristics. Pediatr Dev Pathol 2000; 3:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/25\">",
"      Ley D, Mars&aacute;l K. Doppler velocimetry in cerebral vessels of small for gestational age infants. Early Hum Dev 1992; 31:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/26\">",
"      Grafe MR. The correlation of prenatal brain damage with placental pathology. J Neuropathol Exp Neurol 1994; 53:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/27\">",
"      Burke CJ, Tannenberg AE. Prenatal brain damage and placental infarction--an autopsy study. Dev Med Child Neurol 1995; 37:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/28\">",
"      Burke C, Gobe G. Pontosubicular apoptosis (\"necrosis\") in human neonates with intrauterine growth retardation and placental infarction. Virchows Arch 2005; 446:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/29\">",
"      Blair E, de Groot J, Nelson KB. Placental infarction identified by macroscopic examination and risk of cerebral palsy in infants at 35 weeks of gestational age and over. Am J Obstet Gynecol 2011; 205:124.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/30\">",
"      Naeye RL, Maisels MJ, Lorenz RP, Botti JJ. The clinical significance of placental villous edema. Pediatrics 1983; 71:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/31\">",
"      Redline RW, Wilson-Costello D, Borawski E, et al. The relationship between placental and other perinatal risk factors for neurologic impairment in very low birth weight children. Pediatr Res 2000; 47:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/32\">",
"      Hansen AR, Collins MH, Genest D, et al. Very low birthweight Infant's placenta and its relation to pregnancy and fetal characteristics. Pediatr Dev Pathol 2000; 3:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/33\">",
"      Viscardi RM, Sun CC. Placental lesion multiplicity: risk factor for IUGR and neonatal cranial ultrasound abnormalities. Early Hum Dev 2001; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/34\">",
"      Pharoah PO. Risk of cerebral palsy in multiple pregnancies. Clin Perinatol 2006; 33:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/35\">",
"      Pharoah PO, Adi Y. Consequences of in-utero death in a twin pregnancy. Lancet 2000; 355:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/36\">",
"      Gruenwald P, Levin H, Yousem H. Abruption and premature separation of the placenta. The clinical and the pathologic entity. Am J Obstet Gynecol 1968; 102:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/37\">",
"      Myers RE. Four patterns of perinatal brain damage and their conditions of occurrence in primates. Adv Neurol 1975; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/38\">",
"      Volpe JJ, Pasternak JF. Parasagittal cerebral injury in neonatal hypoxic-ischemic encephalopathy: clinical and neuroradiologic features. J Pediatr 1977; 91:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/39\">",
"      Wu YW, Escobar GJ, Grether JK, et al. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003; 290:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/40\">",
"      Redline RW, O'Riordan MA. Placental lesions associated with cerebral palsy and neurologic impairment following term birth. Arch Pathol Lab Med 2000; 124:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/41\">",
"      Redline RW. Severe fetal placental vascular lesions in term infants with neurologic impairment. Am J Obstet Gynecol 2005; 192:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/42\">",
"      Altshuler G, Arizawa M, Molnar-Nadasdy G. Meconium-induced umbilical cord vascular necrosis and ulceration: a potential link between the placenta and poor pregnancy outcome. Obstet Gynecol 1992; 79:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/43\">",
"      Clapp JF 3rd, Stepanchak W, Hashimoto K, et al. The natural history of antenatal nuchal cords. Am J Obstet Gynecol 2003; 189:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/44\">",
"      Clapp JF 3rd, Lopez B, Simonean S. Nuchal cord and neurodevelopmental performance at 1 year. J Soc Gynecol Investig 1999; 6:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/45\">",
"      DeSa, DJ. Intimal cushions in foetal placental veins. J Pathol 1973; 110:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/46\">",
"      Boyd, TK, Gang, DL, Pflueger, S. Mechanical umbilical blood flow obstruction predisposes to placental fetal vascular thrombosis and stillbirth. Pediatr Dev Pathol 2006; 9:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/47\">",
"      Sander CH. Hemorrhagic endovasculitis and hemorrhagic villitis of the placenta. Arch Pathol Lab Med 1980; 104:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/48\">",
"      Kaplan C, Blanc WA, Elias J. Identification of erythrocytes in intervillous thrombi: a study using immunoperoxidase identification of hemoglobins. Hum Pathol 1982; 13:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/49\">",
"      Faxelius G, Raye J, Gutberlet R, et al. Red cell volume measurements and acute blood loss in high-risk newborn infants. J Pediatr 1977; 90:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/50\">",
"      Redline RW, Pappin A. Fetal thrombotic vasculopathy: the clinical significance of extensive avascular villi. Hum Pathol 1995; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/51\">",
"      Shen-Schwarz S, Macpherson TA, Mueller-Heubach E. The clinical significance of hemorrhagic endovasculitis of the placenta. Am J Obstet Gynecol 1988; 159:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/52\">",
"      Redline RW, Ariel I, Baergen RN, et al. Fetal vascular obstructive lesions: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2004; 7:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/53\">",
"      Sander CH, Kinnane L, Stevens NG. Hemorrhagic endovasculitis of the placenta: a clinicopathologic entity associated with adverse pregnancy outcome. Compr Ther 1985; 11:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/54\">",
"      Leistra-Leistra MJ, Timmer A, van Spronsen FJ, et al. Fetal thrombotic vasculopathy in the placenta: a thrombophilic connection between pregnancy complications and neonatal thrombosis? Placenta 2004; 25 Suppl A:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/55\">",
"      McDonald DG, Kelehan P, McMenamin JB, et al. Placental fetal thrombotic vasculopathy is associated with neonatal encephalopathy. Hum Pathol 2004; 35:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/56\">",
"      Kraus FT, Acheen VI. Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol 1999; 30:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/57\">",
"      Vern TZ, Alles AJ, Kowal-Vern A, et al. Frequency of factor V(Leiden) and prothrombin G20210A in placentas and their relationship with placental lesions. Hum Pathol 2000; 31:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/58\">",
"      Redline RW. Clinical and pathological umbilical cord abnormalities in fetal thrombotic vasculopathy. Hum Pathol 2004; 35:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/59\">",
"      Fritz MA, Christopher CR. Umbilical vein thrombosis and maternal diabetes mellitus. J Reprod Med 1981; 26:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/60\">",
"      Russell P. Inflammatory lesions of the human placenta. III. The histopathology of villitis of unknown aetiology. Placenta 1980; 1:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/61\">",
"      Knox WF, Fox H. Villitis of unknown aetiology: its incidence and significance in placentae from a British population. Placenta 1984; 5:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/62\">",
"      Redline RW, Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. Am J Pathol 1993; 143:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/63\">",
"      Andres RL, Kuyper W, Resnik R, et al. The association of maternal floor infarction of the placenta with adverse perinatal outcome. Am J Obstet Gynecol 1990; 163:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/64\">",
"      Bendon RW, Hommel AB. Maternal floor infarction in autoimmune disease: two cases. Pediatr Pathol Lab Med 1996; 16:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/65\">",
"      Sebire NJ, Backos M, Goldin RD, Regan L. Placental massive perivillous fibrin deposition associated with antiphospholipid antibody syndrome. BJOG 2002; 109:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/66\">",
"      Naeye RL. Maternal floor infarction. Hum Pathol 1985; 16:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/67\">",
"      Adams-Chapman I, Vaucher YE, Bejar RF, et al. Maternal floor infarction of the placenta: association with central nervous system injury and adverse neurodevelopmental outcome. J Perinatol 2002; 22:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/68\">",
"      Harris BA Jr. Peripheral placental separation: a review. Obstet Gynecol Surv 1988; 43:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/69\">",
"      Elliott JP, Gilpin B, Strong TH Jr, Finberg HJ. Chronic abruption-oligohydramnios sequence. J Reprod Med 1998; 43:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/70\">",
"      Redline RW, Wilson-Costello D. Chronic peripheral separation of placenta. The significance of diffuse chorioamnionic hemosiderosis. Am J Clin Pathol 1999; 111:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/71\">",
"      Ohyama M, Itani Y, Yamanaka M, et al. Maternal, neonatal, and placental features associated with diffuse chorioamniotic hemosiderosis, with special reference to neonatal morbidity and mortality. Pediatrics 2004; 113:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/72\">",
"      Nelson KB, Ellenberg JH. Obstetric complications as risk factors for cerebral palsy or seizure disorders. JAMA 1984; 251:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/73\">",
"      Pijnenborg, R. The placental bed. Hypertens Pregnancy 1996; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/74\">",
"      Redline RW, Boyd T, Campbell V, et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol 2004; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/75\">",
"      Stanek J, Al-Ahmadie HA. Laminar necrosis of placental membranes: a histologic sign of uteroplacental hypoxia. Pediatr Dev Pathol 2005; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/76\">",
"      Driscoll, SG. The pathology of pregnancy complicated by diabetes mellitus. Med Clin N Am 1965; 49:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/77\">",
"      Stallmach T, Hebisch G, Meier K, et al. Rescue by birth: defective placental maturation and late fetal mortality. Obstet Gynecol 2001; 97:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/78\">",
"      Hermansen MC. Nucleated red blood cells in the fetus and newborn. Arch Dis Child Fetal Neonatal Ed 2001; 84:F211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/79\">",
"      Blackwell SC, Hallak M, Hotra JW, et al. Timing of fetal nucleated red blood cell count elevation in response to acute hypoxia. Biol Neonate 2004; 85:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/80\">",
"      Altshuler G. Chorangiosis. An important placental sign of neonatal morbidity and mortality. Arch Pathol Lab Med 1984; 108:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/81\">",
"      Stanek, J. Numerical criteria for the diagnosis of placental chorangiosis using CD34 immunostaining. Trophoblast Res 1999; 13:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/82\">",
"      Soma H, Watanabe Y, Hata T. Chorangiosis and chorangioma in three cohorts of placentas from Nepal, Tibet, and Japan. Reprod Fertil Dev 1995; 7:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/83\">",
"      Kadyrov M, Kosanke G, Kingdom J, Kaufmann P. Increased fetoplacental angiogenesis during first trimester in anaemic women. Lancet 1998; 352:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/84\">",
"      Pfarrer C, Macara L, Leiser R, Kingdom J. Adaptive angiogenesis in placentas of heavy smokers. Lancet 1999; 354:303.",
"     </a>",
"    </li>",
"    <li>",
"     Redline, RW. Placental lesions and neurologic outcome. In: The Placenta and Neurodisability, Baker, P, Sibley, C (Eds), MacKeith Press, London, UK 2006. p. 58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21929/abstract/86\">",
"      Langston C, Kaplan C, Macpherson T, et al. Practice guideline for examination of the placenta: developed by the Placental Pathology Practice Guideline Development Task Force of the College of American Pathologists. Arch Pathol Lab Med 1997; 121:449.",
"     </a>",
"    </li>",
"    <li>",
"     Kraus, FT, Redline, RW, Gersell, et al. Chapter 13: Examination Technique. In Placental Pathology, Armed Forces Institute of Pathology Non-tumor Diagnostic Pathology Series, American Registry of Pathology, Washington DC, 2004.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2285 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-5DB13EDD60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21929=[""].join("\n");
var outline_f21_26_21929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PLACENTAL LESIONS IN PRETERM DELIVERIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal vasculitis and histological chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Severe maternal vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Villous edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Multiple placental lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PLACENTAL LESIONS IN TERM DELIVERIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Abruptio placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Complete umbilical cord occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fetal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Subacute processes (partial prolonged hypoxia)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - HCA and severe acute fetal vasculitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Meconium exposure with fetal vascular necrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic intermittent umbilical cord occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Subacute abruption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Active chronic placental disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Fetal thrombotic vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chronic villitis with obliterative fetal vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Massive perivillous fibrin deposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chronic peripheral placental separation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Chronic placental insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Maternal underperfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Macrosomia, placentomegaly, distal villous immaturity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Stressful intrauterine environment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Increased circulating nucleated red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Villous chorangiosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Multiple placental lesions (preconditioning)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/2285\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/2285|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/23/38258\" title=\"picture 1\">",
"      Abruptio placentae gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/28/20933\" title=\"picture 2\">",
"      Obstructed umbilical cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/32/26117\" title=\"picture 3\">",
"      Meconium myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/51/12087\" title=\"picture 4\">",
"      Fetal thrombotic vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/19/32056\" title=\"picture 5\">",
"      Hemorrhagic endovasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/4/37958\" title=\"picture 6\">",
"      Chronic villitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/50/42793\" title=\"picture 7\">",
"      Chronic villitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/17/15637\" title=\"picture 8\">",
"      Maternal floor infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/62/37865\" title=\"picture 9\">",
"      Chronic placenta underperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/34/30248\" title=\"picture 10\">",
"      Chorioangiosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21930="Initial management of regionally localized intermediate and high risk prostate cancer";
var content_f21_26_21930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of regionally localized intermediate and high risk prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     John F Ward, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Brian Davis, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/26/21930/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/26/21930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is increasingly diagnosed in younger men and at an earlier disease stage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, some men with newly diagnosed prostate cancer have more extensive disease (clinical stage T2b or higher), regional lymph node metastases (N1), or other factors associated with an increased risk of local recurrence or progression to disseminated disease (serum PSA &gt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or Gleason score 7 or higher) (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"UTD.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic discusses the initial management approach for men with prostate cancer at increased risk for recurrence and dissemination. The general approaches to the treatment of men with low risk prostate cancer and for those with stage IV disease are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"       \"Overview of the treatment of disseminated prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H511317266\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of men with newly diagnosed prostate cancer needs to incorporate a consideration of the prolonged natural history of prostate cancer and the risk for progression to disseminated, potentially fatal disease.",
"   </p>",
"   <p>",
"    Risk stratification uses the clinical stage of disease, baseline serum prostate specific antigen (PSA) and the Gleason score to divide patients into prognostic categories (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"UTD.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    ). Although there are fairly arbitrary boundaries between these prognostic categories, prostate cancer is a broad continuum. This information is combined with patient age, overall medical condition, and the presence or absence of symptoms to guide initial therapy decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For purposes of this discussion, patients are divided into low, intermediate, and high risk. The high risk category also incorporates the &lsquo;very high risk&rsquo; category used by the National Comprehensive Cancer Network (NCCN).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk prostate cancer &ndash; Patients with clinically localized, low risk prostate cancer either have limited disease in one lobe of the prostate (T2a) or no apparent tumor (T1, diagnosis based upon a biopsy only, with no abnormal findings on imaging or palpation), a serum PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and a Gleason score &le;6.",
"     </li>",
"     <li>",
"      Intermediate-risk prostate cancer &ndash; Men with clinically localized, intermediate-risk prostate cancer can have more extensive tumor in the prostate (ie, involving more than one-half of one lobe of the prostate [T2b] or with bilateral disease [T2c] on initial examination or imaging), but without extracapsular extension or seminal vesicle involvement. In addition, patients with clinical stage T1 or T2a disease are classified as being at intermediate risk based upon a serum PSA between 10 and 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a biopsy Gleason score 7.",
"     </li>",
"     <li>",
"      High risk prostate cancer &ndash; Patients with regionally localized, high risk prostate cancer can have more extensive disease, based upon the presence of extracapsular extension (T3a) by digital rectal examination. Whether this translates to possible extraprostatic disease seen on imaging (eg, MRI) is not known. In addition, some patients with less extensive disease are classified as being at high risk because of a serum PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or a Gleason score of 8 to 10.",
"     </li>",
"     <li>",
"      Patients with lymph node involvement (N1) or disseminated metastases (M1) are classified as having stage IV disease, regardless of the extent of their primary tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment approaches for patients with regionally localized prostate cancer at intermediate or high risk of recurrence are presented in this section. Detailed discussions of issues regarding the roles of radiation therapy (RT) and radical prostatectomy are presented below. (See",
"    <a class=\"local\" href=\"#H181128718\">",
"     'Radiation therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H181131068\">",
"     'Radical prostatectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2952847\">",
"    <span class=\"h2\">",
"     Benefit of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensive data on the benefit of treatment compared with no definitive intervention come from the PIVOT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/3\">",
"     3",
"    </a>",
"    ]. In that trial, prostate-cancer mortality was lower in the radical-prostatectomy group than in the observation group among men with a PSA value of more than 10 ng per milliliter (5.6 versus 12.8 percent, p = 0.02) and among men with high risk prostate cancer (9.1 versus 17.5 percent, p = 0.04).",
"   </p>",
"   <p>",
"    Additional indirect evidence on the benefit of treatment comes from phase III trials that compare RT plus ADT versus ADT alone (",
"    <a class=\"graphic graphic_table graphicRef54425 \" href=\"UTD.htm?2/12/2252\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In the largest of these, 1205 patients were randomly assigned to lifelong ADT plus RT or lifelong ADT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients had clinical T3 or T4 disease in 88 percent of cases. The remainder had clinical T2 disease with either a PSA &gt;40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and a Gleason score of 8 to 10. ADT consisted of either a gonadotropin releasing hormone agonist or bilateral orchiectomy. The total RT dose was 65 to 69 Gy over 7 to 7.5 weeks.",
"    <br/>",
"    <br/>",
"    A final report of this trial was presented at the 2012 American Society of Clinical Oncology (ASCO) meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/7\">",
"     7",
"    </a>",
"    ]. The 10 year overall survival was significantly increased with the combination of RT plus ADT compared with ADT alone (55 versus 49 percent, HR 0.70, 95% CI 0.57-0.85). Similarly, the death rate due to prostate cancer was decreased (15 versus 26 percent, HR 0.46, 95% CI 0.34-0.61). These results were obtained despite using a lower radiation dose than is now considered optimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H14#H14\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Dose and schedule'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2951830\">",
"    <span class=\"h2\">",
"     Clinically localized intermediate risk prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with clinically localized prostate cancer are classified as intermediate-risk if they have more extensive tumor in the prostate (involving more than one-half of one lobe of the prostate [T2b] or with bilateral disease [T2c]) compared with low risk disease, but without extracapsular extension or seminal vesicle involvement. Patients with clinical stage T1 or T2a disease are also classified as having intermediate risk disease if they have a serum PSA between 10 and 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a Gleason score 7 on the biopsy.",
"   </p>",
"   <p>",
"    Treatment options for men with intermediate risk disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT, which is usually combined with androgen deprivation therapy (ADT). RT may be given by either external beam or external beam in combination with brachytherapy. (See",
"      <a class=\"local\" href=\"#H181128718\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radical prostatectomy, including pelvic lymph node dissection if the predicted probability of lymph node involvement is 2 percent or more. Following surgery, patients are restaged pathologically. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Pathologic versus clinical staging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with adverse histologic features (extracapsular extension, seminal vesicle involvement, positive margins) or a persistent elevation of the serum PSA after surgery, postoperative adjuvant RT is probably indicated. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H255203697#H255203697\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2951838\">",
"    <span class=\"h2\">",
"     Regionally localized high risk prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with regionally localized prostate cancer are classified as having high risk disease, based upon the presence of extracapsular extension (T3a), seminal vesicle involvement (T3b), or tumor fixation to or invasion of adjacent structures (T4). In addition, patients with anatomically less extensive disease are classified as high risk based upon a serum PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a Gleason score of 8 to 10.",
"   </p>",
"   <p>",
"    Treatment options for these men include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation therapy (RT), which is usually combined with androgen deprivation therapy (ADT) for two to three years. Combining RT with ADT in this fashion confers a survival benefit compared to either treatment alone based upon results from phase III studies. RT may also be combined with brachytherapy but no Phase III trials testing the optimal duration of ADT in this setting have been completed. Therefore, using a similar duration of ADT with combined therapy may be most appropriate although some organizations advocate limiting ADT to a shorter duration (four to six months) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H181128718\">",
"       'Radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radical prostatectomy including pelvic lymph node dissection. Surgery is limited to patients without tumor fixation. Following surgery, patients are restaged pathologically. For patients with adverse histologic features (extracapsular extension, seminal vesicle involvement, positive margins) or a persistent elevation of the serum PSA, postoperative adjuvant RT may be indicated. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H255203697#H255203697\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some men who undergo radical prostatectomy, pelvic lymph node dissection will identify previously unsuspected histopathologic involvement of regional lymph nodes. In such cases, surgery may have been curative. In this setting, the serum PSA provides important information on whether or not all disease has been resected and whether further therapy is indicated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients in whom the serum PSA is undetectable following definitive surgery, careful monitoring is indicated including digital rectal examination and serum PSA every three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"       \"Follow-up surveillance during and after treatment for prostate cancer\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      If the PSA fails to fall to undetectable levels or if the PSA subsequently rises, patients are presumed to have residual or recurrent disease. Such patients should be evaluated for evidence of metastatic disease, and subsequent therapy is dictated by the results of that evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32353885\">",
"    <span class=\"h2\">",
"     Clinical evidence of lymph node involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with prostate cancer and clinical evidence of lymph node diagnosis, RT in combination with systemic ADT is the standard treatment if their overall condition permits aggressive therapy. In this clinical setting, RT should include the whole pelvis. (See",
"    <a class=\"local\" href=\"#H181128733\">",
"     'Prostate only versus whole pelvis RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no randomized trials that were conducted exclusively in men with clinical evidence of lymph node involvement which compare RT alone versus RT plus androgen deprivation therapy (ADT). However, the available data in patients with high risk disease and trials that included some patients with lymph node involvement demonstrated that the addition of ADT improves local control and decreases the incidence of distant metastases. (See",
"    <a class=\"local\" href=\"#H2956464\">",
"     'External beam RT plus ADT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal duration of ADT is controversial. For men with high risk disease, the available data suggest that prolonged therapy is more beneficial than a short course of treatment. Extrapolating from the experience with patients with regionally localized high risk prostate cancer, ADT should be continued for two to three years. (See",
"    <a class=\"local\" href=\"#H181128747\">",
"     'Duration and timing of ADT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128718\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128726\">",
"    <span class=\"h2\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam RT can be used to treat intermediate or high risk prostate cancer and is generally given in combination with ADT. Contemporary RT for prostate cancer utilizes three-dimensional conformal techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H2#H2\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'External beam RT techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key issues in the use of external beam RT to treat intermediate and high risk prostate cancer and locally advanced disease include whether or not to treat the whole pelvis as well as the prostate and the role of ADT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128733\">",
"    <span class=\"h3\">",
"     Prostate only versus whole pelvis RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic status of the pelvic lymph nodes is generally not known (Nx) in men who will be treated with RT.",
"   </p>",
"   <p>",
"    Clinical staging based upon imaging frequently fails to detect lymph node involvement. In patients with clinical T3 prostate cancer who are managed with radical prostatectomy and thus have full pathologic staging, approximately one quarter are found to have occult lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, RT to the pelvic lymph nodes is frequently advocated in men with a significant likelihood of having disease in the regional nodes.",
"   </p>",
"   <p>",
"    Two randomized trials directly addressed the role of whole pelvis RT compared to prostate only RT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In RTOG trial 9413, 1323 men with regionally localized disease and an estimated risk of nodal metastases &ge;15 percent were randomly assigned to whole pelvis RT (1.8 Gy per fraction, with 50.4 Gy to the pelvis and 70.2 Gy to the prostate) or prostate-only RT (70.2 Gy) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. Patients were further randomized, using a 2 x 2 factorial design, to neoadjuvant plus concurrent ADT (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      ) administered for two months before and during RT, or adjuvant ADT with the same drugs given for the same length of time, but starting after the completion of RT. The majority of enrolled men had T2c or higher stage disease, a serum PSA &lt;30",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      and a Gleason score of 7 or higher; thus, they fell into the intermediate and high risk categories.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 6.6 years, there were no significant differences in progression-free survival (PFS) or overall survival when men treated with whole pelvis RT were compared to those managed with prostate-only RT [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/11\">",
"       11",
"      </a>",
"      ]. However, there appeared to be an interaction between ADT and radiation treatment volume size. Within the group that received whole pelvis RT, there was a trend toward better progression-free survival (PFS) and overall survival with neoadjuvant plus concurrent as compared to adjuvant only ADT. However, the study was insufficiently powered to show a statistically significant difference between these two treatment arms.",
"     </li>",
"     <li>",
"      In the GETUG-01 trial 446 men were randomly assigned to whole pelvis RT or prostate-only RT [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/13\">",
"       13",
"      </a>",
"      ]. At a median follow-up of 42 months, the five-year PFS and overall survival were not significantly different in the two treatment arms. Multiple factors may have contributed to a lack of benefit from whole pelvis RT. In contrast to RTOG 9413, over one-half of the patients had an estimated risk of lymph node involvement of less than 15 percent. In addition, the dose of RT to the prostate and pelvis was less than 70 Gy to the prostate in over one-half of the patients, and the RT treatment volume for those receiving pelvic RT was smaller than in the RTOG trial. Furthermore GETUG-01 used the older ASTRO definition of biochemical failure, which is suboptimal in patients who receive ADT [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study and longer follow-up are needed before a standard of care can be recommended. The RTOG is currently conducting a randomized, phase III trial (RTOG 0924, NCT01368588), in which patients with high risk or locally advanced prostate cancer receive ADT in conjunction with either prostate only or whole pelvis RT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon currently available results, whole pelvis RT can be considered in cases where the risk of lymph node involvement is greater than 15 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2956464\">",
"    <span class=\"h3\">",
"     External beam RT plus ADT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2953368\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ADT in combination with external beam RT has traditionally been the standard treatment for men receiving RT for regionally localized high risk prostate cancer based upon improvements in cancer-specific and overall survival observed in multiple randomized trials. There is increasing interest in and study of surgery for these patients as part of a multimodal treatment.",
"   </p>",
"   <p>",
"    This is illustrated by the results of three major cooperative group trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In RTOG 86-10 trial, 471 men with T2-T4 tumors measuring at least 5 x 5 cm were randomly assigned to RT with or without ADT (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"       flutamide",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/16\">",
"       16",
"      </a>",
"      ]. ADT was administered for two months before and two months during RT.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 12.5 years, ADT significantly decreased the 10-year disease-specific mortality, distant metastases, and biochemical failure rates (23 versus 36, 35 versus 47, and 65 versus 80 percent without ADT) while increasing the 10-year disease-free survival rate (11 versus 3 percent). The 10-year overall survival rate was increased at 10 years (43 versus 34 percent), although this difference was not statistically significant (p = 0.12).",
"     </li>",
"     <li>",
"      In the EORTC 22863 trial, 415 men with poor-risk prostate cancer (clinical stage T1-4,N0) were randomly assigned to external beam RT alone or external beam RT with three years of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      (starting on the first day of RT) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"       cyproterone",
"      </a>",
"      (150 mg per day) for one month, starting one week before the first goserelin injection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At a median follow-up of nine years, the 10-year disease-free survival was significantly improved with the addition of ADT compared to RT alone (48 versus 23 percent, hazard ratio [HR] 0.42, 95% CI 0.33-0.53). Similarly, the 10-year overall survival was better with the combination treatment (58 versus 40 percent, HR 0.60, 95% CI 0.45-0.80), and prostate cancer mortality was decreased (10 versus 30 percent, HR 0.38, 95% CI 0.24-0.60).",
"     </li>",
"     <li>",
"      In RTOG 85-31, 977 men with cT3 or pT3 prostate cancer with or without regional nodal involvement were randomly assigned to long-term adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"       goserelin",
"      </a>",
"      (started during the last week of RT and continued indefinitely or until disease progression) or RT alone followed by observation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/18\">",
"       18",
"      </a>",
"      ]. The addition of ADT significantly decreased the rates of local failure and distant metastases (23 versus 38 percent and 24 versus 39 percent, respectively, compared to observation). The 10-year overall and cause-specific survival rates were improved (49 versus 39 and 22 versus 16 percent, respectively). Subgroup analysis suggested that ADT preferentially benefited men with higher Gleason scores; outcomes were not improved in those with a Gleason score 2 to 6.",
"      <br/>",
"      <br/>",
"      In a subset analysis of the 173 men with node-positive disease, adjuvant ADT significantly improved five-year bRFS (54 versus 33 percent without ADT) and decreased the rate of distant metastases. The differences in five-year overall (72 versus 62 percent) and cause-specific survival were not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be an increased risk of cardiovascular disease in patients treated with ADT. However, the benefits of ADT appear to outweigh the risks in patients treated appropriately with ADT. A meta-analysis that incorporated data from eight phase III trials showed that the incidence of cardiovascular death was not significantly different in those treated with ADT compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H22#H22\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Cardiovascular disease and diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128747\">",
"    <span class=\"h4\">",
"     Duration and timing of ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged treatment with ADT has been shown to be beneficial in men with high risk localized prostate cancer and may also be effective in men with intermediate risk disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. However, the optimal duration of treatment has not been definitively determined.",
"   </p>",
"   <p>",
"    In the largest trial (RTOG 92-02), 1554 men with T2c-T4 disease received four months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9574?source=see_link\">",
"     goserelin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    (two months before and during external beam RT), and were then randomly assigned to no further therapy or 24 months of additional goserelin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. At the most recent follow-up, long-term ADT significantly reduced 10-year rates of biochemical failure, local recurrence, and distant metastases (52 versus 68, 12 versus 22, and 15 versus 23 percent, respectively, compared to short-term ADT) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/24\">",
"     24",
"    </a>",
"    ]. Similarly, long-term ADT significantly improved the 10-year disease-free and disease-specific survival rates (23 versus 13 and 88 versus 84 percent) but not overall survival (54 versus 52 percent). In a post-randomization analysis, overall 10-year survival was significantly increased with long-term ADT in the subset of men with a Gleason score of 8 to 10 (45 versus 32 percent).",
"   </p>",
"   <p>",
"    An overall survival benefit with a longer duration of ADT was observed in EORTC trial 22961 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/25\">",
"     25",
"    </a>",
"    ]. In this trial, 970 men undergoing RT for locally advanced or node-positive disease (T1-2, N1-2, or T2c-4, N0-2, (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"UTD.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    )) received six months of complete androgen blockade and were then randomly assigned to observation or 2.5 years of additional treatment with a gonadotropin releasing hormone agonist. At a median follow-up of 6.4 years, the prolonged course of ADT was associated with a significant decrease in overall mortality compared to the six month course of treatment (five-year mortality rate 15.2 versus 19.0 percent, hazard ratio 0.70, 95% CI 0.55-0.92).",
"   </p>",
"   <p>",
"    In another trial evaluating an intermediate duration of treatment, 630 men with high risk",
"    <span class=\"nowrap\">",
"     (T3/4,",
"    </span>",
"    PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/ml,",
"    </span>",
"    or Gleason score &gt;7), node negative prostate cancer were randomly assigned to either 18 or 36 months of ADT, beginning prior to RT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/28\">",
"     28",
"    </a>",
"    ]. Preliminary results were presented at the 2013 ASCO GU symposium. At a median follow-up of over six years, there were no statistically significant differences in overall survival or rates of treatment failure, although the trial was not powered to demonstrate equivalence.",
"   </p>",
"   <p>",
"    The main drawback of using ADT for a prolonged period is the higher incidence of clinically important side effects, such as impotence, loss of libido, osteoporosis, and possibly cardiovascular issues, although there does not appear to be an increase in cardiovascular mortality. Results of a phase III trial in which treatment with six months of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    was compared with 18 months in patients with locally advanced prostate cancer indicated that the longer course of adjuvant therapy was associated with increased side effects but that these differences largely resolved with time [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link\">",
"     \"Side effects of androgen deprivation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional information on the role of ADT in men with intermediate risk disease should be derived from the RTOG 0815 trial (NCT00936390) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/30\">",
"     30",
"    </a>",
"    ]. In that phase III trial, all men with intermediate risk prostate cancer are treated with RT (either external beam or external beam plus brachytherapy). Patients are randomized to receive six months of ADT (beginning two months prior to RT) or to no ADT.",
"   </p>",
"   <p>",
"    The optimal timing of RT in men who are treated with neoadjuvant ADT is uncertain. In most studies, RT was started two months after institution of ADT. The benefit of delaying the start of RT until a maximal response to ADT is achieved is under study in RTOG trial 99-10 (NCT00005044), which compares two months versus seven months of neoadjuvant ADT prior to RT in men with intermediate risk prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/31\">",
"     31",
"    </a>",
"    ]. Enrollment is complete and results are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3123062\">",
"    <span class=\"h4\">",
"     Choice of ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether ADT should consist of a gonadotropin releasing hormone (GnRH) agonist alone or whether an antiandrogen such should be added during treatment initiation has not been addressed in a randomized trial. Data from an observational study support the addition of an antiandrogen, but this was derived from a series in which ADT was given for a median duration of four months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current protocols from the Radiation Therapy Oncology Group use an antiandrogen in combination with a GnRH agonist during the first four months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128754\">",
"    <span class=\"h3\">",
"     External beam RT plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy does not have an established role as part of a combined modality approach to the treatment of high risk or locally advanced prostate cancer. An initial trial (RTOG 99-02) evaluated the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/4/35909?source=see_link\">",
"     estramustine",
"    </a>",
"    in addition to ADT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/33\">",
"     33",
"    </a>",
"    ]. That trial was terminated early because of increased toxicity associated with the addition of chemotherapy to ADT.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    , given every three weeks with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , is now the preferred initial chemotherapy regimen in patients with metastatic disease. The docetaxel plus prednisone regimen has been incorporated into the ongoing RTOG 0521 trial (NCT00288080) in which adjuvant ADT is compared to adjuvant ADT plus chemotherapy in patients at high risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=see_link&amp;anchor=H8#H8\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Chemotherapy-naive patients: docetaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128761\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of external beam RT for prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H19#H19\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128768\">",
"    <span class=\"h2\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachytherapy allows escalation of the dose of radiation to the prostate beyond that readily achievable with external beam RT. Although brachytherapy is primarily utilized for patients with low and intermediate risk disease, its use in men with high risk disease, either alone or in combination with ADT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    external beam RT, is increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/34\">",
"     34",
"    </a>",
"    ]. Both high dose rate (HDR) brachytherapy and low dose rate (LDR) brachytherapy are being utilized in patients with locally advanced prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link\">",
"     \"Brachytherapy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increased effective dose of radiation is associated with the improved local control and a decreased incidence of PSA relapse. Whether external beam RT plus brachytherapy, using either a HDR or LDR technique, is superior to external beam RT alone using doses &ge;72 Gy in men with high risk prostate cancer remains unclear. Despite the limited evidence in this setting, brachytherapy in conjunction with external beam RT plus ADT for men with high risk disease is becoming more commonplace in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128775\">",
"    <span class=\"h3\">",
"     HDR brachytherapy plus external beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of combining high dose rate brachytherapy with external beam RT was evaluated in the multicenter RTOG 0321 study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with high risk or prostate cancer (T1c-T3b) were treated with external beam RT (45 Gy in 25 fractions) plus HDR brachytherapy (19 Gy in two fractions). At a median follow-up of 2.5 years, 125 patients were evaluable; the rate of late grade 3 or greater gastrointestinal or genitourinary adverse events was 2.6 percent at 18 months.",
"   </p>",
"   <p>",
"    The combination of brachytherapy plus external beam RT was compared with external beam RT alone in two small randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 104 men with cT2 or cT3 prostate cancer were randomly assigned to external beam RT alone (66 Gy in 2 Gy fractions) or external beam RT (40 Gy) preceded by a single transperineal temporary implantation of iridium-192 (35 Gy) brachytherapy given over 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/36\">",
"       36",
"      </a>",
"      ]. At a median follow-up of eight years, the rate of biochemical or clinical failure was significantly lower in the HDR brachytherapy plus external beam RT group (29 versus 61 percent), although overall survival was similar.",
"     </li>",
"     <li>",
"      In another trial, 218 patients were randomly assigned to external beam RT alone (55 Gy in 20 fractions over four weeks) or external beam RT (35.75 Gy in 13 fractions over 2.5 weeks) plus HDR brachytherapy (17 Gy divided into two fractions over 24 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/37\">",
"       37",
"      </a>",
"      ]. In a secondary report of this trial with follow-up extending up to ten years, relapse-free survival was significantly longer with the combined treatment, but there was no improvement in overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interpretation of these trials is complicated by the variable dose and fractionation schedules used with the external beam RT and HDR brachytherapy, as well as the small size and short follow-up of these trials.",
"   </p>",
"   <p>",
"    HDR brachytherapy alone may not adequately encompass sites of extracapsular spread. Combining HDR brachytherapy with external beam may improve outcomes in men with intermediate- or high risk disease. This combined approach is being studied using LDR brachytherapy in combination with external beam RT in the ongoing multicenter phase III clinical trial (RTOG 0232, NCT00063882) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128782\">",
"    <span class=\"h3\">",
"     LDR brachytherapy plus external beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose rate (LDR) brachytherapy is also being employed in combination with external beam RT in men with high risk prostate cancer. Observational studies suggest that this strategy is well tolerated and may be similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a combined series from six centers, 1078 men with Gleason scores 7 or 8 to 10 (78 and 22 percent, respectively) were treated with LDR brachytherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/40\">",
"     40",
"    </a>",
"    ]. External beam RT was given with brachytherapy in 58 percent of cases. Biochemical freedom from failure at five years was significantly related to the biologic effective dose (76, 84, and 88 percent for doses &lt;200, 200 to 220, and &gt;220 Gy, respectively). In patients with Gleason 8 to 10 cancers, there was a trend toward improved five-year overall survival based upon dose (87, 89, and 95 percent, respectively).",
"   </p>",
"   <p>",
"    In a phase III trial being conducted by the Radiation Therapy Oncology Group (RTOG 0232, NCT00063882), patients with intermediate risk prostate cancer were randomly assigned to LDR permanent prostate brachytherapy with or without external beam RT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/43\">",
"     43",
"    </a>",
"    ]. Results are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181128789\">",
"    <span class=\"h3\">",
"     Brachytherapy plus ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that have evaluated the role of ADT in patients treated with brachytherapy, either alone or with external beam RT, for intermediate or high risk prostate cancer.",
"   </p>",
"   <p>",
"    The most extensive observational data come from a multicenter study of 1342 men who were treated with brachytherapy either alone, with ADT, with external beam RT, or with both ADT and external beam RT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients had high risk or locally advanced disease, defined by a serum PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    clinical T3 or T4 disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a Gleason score 8 to 10. ADT was given for an average of four months and was completed prior to brachytherapy. Median follow-up was five years.",
"   </p>",
"   <p>",
"    Consistent with early reports, factors associated with a poorer prognosis and increased cancer-specific mortality included a clinical stage T2 or T3 primary tumor, a Gleason score of 8 to 10, and a higher serum PSA. A combined modality approach was used more frequently in patients with multiple negative prognostic factors and these patients had a higher mortality. However, multivariate analysis incorporating all of these factors found that prostate cancer-specific mortality was significantly lower in patients treated with brachytherapy plus both external beam RT and ADT compared to brachytherapy alone (adjusted hazard ratio [AHR] 0.32, 95% CI 0.14-0.73).",
"   </p>",
"   <p>",
"    The differences in prostate cancer-specific mortality with brachytherapy plus external beam RT without ADT versus brachytherapy alone and brachytherapy plus ADT without external beam RT versus brachytherapy alone were not statistically significant (AHRs 0.57, 95% CI 0.21-1.52, and 0.63, 95% CI 0.27-1.42, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181131068\">",
"    <span class=\"h1\">",
"     RADICAL PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For relatively young, otherwise healthy men radical prostatectomy is an alternative approach for men with intermediate or high risk regionally localized prostate cancer and for men with locally advanced disease without tumor fixation to adjacent structures or clinical evidence of lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link\">",
"     \"Radical prostatectomy for localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181129794\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical prostatectomy alone is usually insufficient in the management of high risk prostate cancer because of the risk of local recurrence or disseminated metastases. Considerations for adjuvant or salvage therapy following primary treatment should be incorporated into the treatment plan at the very beginning of discussions with a man who has high risk disease.",
"   </p>",
"   <p>",
"    The use of adjuvant therapy for men who have pT3 or margin-positive disease following radical prostatectomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Adjuvant hormone therapy without RT'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181129801\">",
"    <span class=\"h2\">",
"     Neoadjuvant ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant ADT may decrease tumor volume and improve the rate of complete resection in men with cT3 prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. However, randomized trials have not demonstrated an improvement in long-term outcome.",
"   </p>",
"   <p>",
"    In a review of the available literature, neoadjuvant ADT decreased the serum PSA in almost all men and decreased the incidence of positive resection margins in six of seven randomized prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this was not accompanied by significant differences in operative time, blood loss, transfusion rates, or length of hospital stay. Moreover, there was no improvement in the rate of lymph node metastasis, biochemical relapse-free survival, or overall survival.",
"   </p>",
"   <p>",
"    Investigational approaches have added chemotherapy to ADT (chemohormonal therapy), based primarily upon the activity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    in patients with advanced disease. However, the addition of chemotherapy has not been consistently demonstrated to have significant antitumor effects as assessed by histologic changes in the radical prostatectomy specimens or a reduction in the incidence of adverse pathologic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=see_link\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized phase III clinical trial (CALGB 90203) is currently comparing neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus ADT followed by radical prostatectomy versus immediate radical prostatectomy (NCT00430183) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/15\">",
"     15",
"    </a>",
"    ]. Eligible patients should be encouraged to participate whenever possible.",
"   </p>",
"   <p>",
"    The role of RT in patients with positive lymph nodes identified at radical prostatectomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H1302123#H1302123\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Microscopic lymph node involvement'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191259\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from randomized clinical trials that adequately compare RT with radical prostatectomy for men with intermediate or high risk prostate cancer, nor is it likely that such studies will be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparisons between different treatment modalities rely upon interpretation of large, observational databases. Interpretation of such data requires that studies have adequate follow-up, stratify patients based upon pretreatment criteria, utilize standard definitions for treatment success or failure, and contain adequate numbers of patients. In these observational databases, the criteria for biochemical progression-free survival differ; following radical prostatectomy, the PSA is required to be unmeasurable after surgery, while biochemical relapse free following RT and brachytherapy uses a definition of nadir + 2.0",
"    <span class=\"nowrap\">",
"     ng/ml.",
"    </span>",
"   </p>",
"   <p>",
"    The Prostate Cancer Results Study Group reviewed all studies published between 2000 and 2010 for published reports meeting those criteria. That analysis suggested that brachytherapy was associated with better biochemical progression-free survival at five years, although it is unclear whether this may simply reflect differences in patient selection.",
"   </p>",
"   <p>",
"    Representative studies identified in that review illustrate the results in men with intermediate or high risk prostate cancer. The results from these observational studies cannot be used for definitive comparisons between different treatment approaches. However, these studies do provide important information about the long-term outcomes for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191458\">",
"    <span class=\"h2\">",
"     Clinically localized, intermediate risk disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191266\">",
"    <span class=\"h3\">",
"     Radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results using radical retropubic prostatectomy to treat prostate cancer are illustrated by a series of 2795 men with intermediate risk prostate cancer treated at the Mayo Clinic between 1987 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/47\">",
"     47",
"    </a>",
"    ]. Approximately 50 percent of these cases had clinical stage T2b disease, while the remainder were classified as intermediate risk based upon a serum PSA of 10 &ndash; 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a Gleason score of 7; the median follow-up was 7.7 years.",
"   </p>",
"   <p>",
"    At five years, 78 percent were free from biochemical relapse, and at 10 years 65 percent remained biochemically progression free. Even among those who experienced a biochemical relapse, the prognosis for these low risk patients was highly favorable. The overall rates of freedom from local recurrence were 96 and 92 percent at 5 and 10 years, respectively, and the freedom from systemic progression was 96 and 89 percent at 5 and 10 years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191273\">",
"    <span class=\"h3\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes with external beam RT as a single modality are illustrated by a single institution series of 2047 men treated between 1998 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/48\">",
"     48",
"    </a>",
"    ]. The series included 849 patients with intermediate-risk disease. RT was administered either by 3D-CRT or IMRT, with doses ranging from 66 to 86 Gy.",
"   </p>",
"   <p>",
"    The seven-year PSA relapse-free survival rate for intermediate-risk disease patients was 72 percent. The distant metastasis-free and cause-specific survival rates at seven years for men with intermediate-risk disease were 92 and 94 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191280\">",
"    <span class=\"h3\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results with low dose rate brachytherapy using permanent seed implantation are illustrated by a multi institution series of 2693 patients treated between 1988 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/49\">",
"     49",
"    </a>",
"    ]. Median follow-up was five years. Within this series, 960 had intermediate-risk disease. Two-thirds of patients were treated with iodine-125 and the remainder with palladium-103.",
"   </p>",
"   <p>",
"    The eight-year PSA relapse-free survival rate was 70 percent according to the ASTRO definition (progression defined by three successive increases in the PSA after the nadir was reached) and 61 percent according to the Phoenix (nadir +2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    definition. The eight-year distant metastasis free survival for the intermediate-risk patients was 92 percent. Multivariate analysis confirmed the importance of an adequate dose of radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969519\">",
"    <span class=\"h3\">",
"     External beam RT plus brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External beam RT has been combined with brachytherapy to increase the dose of radiation to the primary tumor and thus reduce the risk of local recurrence. These combination approaches have used both low-dose rate brachytherapy and high dose rate brachytherapy. In observational studies these approaches have yielded PSA recurrence free survival rates of 80 to 90 percent at five to ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], which are similar to those with other primary treatment approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191562\">",
"    <span class=\"h2\">",
"     Regionally localized, high risk disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191505\">",
"    <span class=\"h3\">",
"     Radical prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical retropubic prostatectomy was used to treat 1513 men with high risk prostate cancer at the Mayo Clinic between 1987 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/47\">",
"     47",
"    </a>",
"    ]. Bilateral involvement was present in 60 percent of cases (T2c), and the Gleason score was 7 or 8-10 in 24 and 23 percent of cases, respectively. Median follow-up was 7.7 years. The biochemical relapse&ndash;free survival rates at 5 and 10 years were 68 and 55 percent, respectively. For high risk patients the 10 year local recurrence-free survival rate was 90 percent, and the 10 year systemic progression-free survival rate was 89 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191512\">",
"    <span class=\"h3\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes with external beam RT as a single modality are illustrated by a single institution series of 2047 men treated between 1998 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/48\">",
"     48",
"    </a>",
"    ]. The series included 752 patients with high risk disease. RT was administered without brachytherapy boost either by 3D-CRT or IMRT, with doses ranging from 66 to 86 Gy. The seven-year PSA relapse-free survival rates for men with high risk disease was 54 percent. The distant metastasis-free survival rate was 76 percent at seven years, and the cause-specific survival rate was 81 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191519\">",
"    <span class=\"h3\">",
"     Brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results with low dose rate brachytherapy using permanent seed implantation are illustrated by a multi institution series of 2693 treated between 1988 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/49\">",
"     49",
"    </a>",
"    ]. Median follow-up was five years. Within this series, 192 had high risk disease. The patient population in this series constituted a carefully selected subset of the high risk patient population. Only patients with T1 or T2 disease were included; those with T2c (bilateral) disease, a PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or a Gleason score of 8 to 10 were classified as high risk, but high risk patients with T3 disease were excluded.",
"   </p>",
"   <p>",
"    The eight-year PSA relapse-free survival rate for this group of high risk patients was 48 percent according to the ASTRO definition (three successive increases in the PSA after nadir reached) and 39 percent according to the Phoenix (nadir +2",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    definition. The eight-year distant metastasis free survival 91 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1969587\">",
"    <span class=\"h3\">",
"     External beam RT plus brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brachytherapy boost in conjunction with external beam RT has been used to improve local control in patients with high risk prostate cancer. These combined modality approaches, which have used both low-dose rate brachytherapy and high dose rate brachytherapy, have given biochemical control rates of 65 to 90 percent at five to ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2956530\">",
"    <span class=\"h2\">",
"     Locally advanced (T3b, T4) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are less extensive data on the prognosis of patients with locally advanced (T3b, T4) disease based upon pretreatment evaluation. In one prospective phase II study, as an example, 62 patients with T3 or T4 prostate cancer were treated with neoadjuvant hormonal therapy followed by radical prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/53\">",
"     53",
"    </a>",
"    ]. The estimated 10 year progression-free survival was 40 percent, and the 10 year overall survival estimate was 68 percent. Similar results were seen in a single institution analysis of patients undergoing radical prostatectomy for high risk disease, although the majority of patients in that series were high risk based upon the degree of PSA elevation or a biopsy Gleason score of 8 or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/54\">",
"     54",
"    </a>",
"    ].These results appear to be similar to those with RT in historical series. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191287\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2950516\">",
"    <span class=\"h2\">",
"     Radical prostatectomy versus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of radical prostatectomy or radiation therapy as the primary treatment modality depends upon an informed patient decision incorporating knowledge about the potential advantages and disadvantages associated with each treatment approach along with personal preferences. The important advantages, disadvantages, and contraindications associated with each approach are discussed separately and are summarized in the appended tables (",
"    <a class=\"graphic graphic_table graphicRef52491 \" href=\"UTD.htm?17/61/18396\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51287 \" href=\"UTD.htm?17/59/18364\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53124 \" href=\"UTD.htm?10/30/10732\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834319#H834319\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Choice of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radical prostatectomy was compared with RT in a Japanese trial in which 100 men with T2b or T3N0M0 prostate cancer were randomly assigned to radical prostatectomy with a pelvic lymph node dissection or to external beam RT (total dose 60 to 70 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/55\">",
"     55",
"    </a>",
"    ]. All patients received endocrine therapy beginning eight weeks prior to treatment and continuing after definitive therapy. At 10 years, patients assigned to radical prostatectomy had a similar biochemical relapse-free survival, cause-specific survival, and overall survival (76 versus 71, 86 versus 77, and 68 versus 61 percent with external beam RT, respectively).",
"   </p>",
"   <p>",
"    Comparisons of outcomes from nonrandomized series are subject to multiple biases, imbalances in relevant prognostic factors, and lack of central pathology review. As a result, no definitive comparison is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181130646\">",
"    <span class=\"h2\">",
"     Palliative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If age or comorbidity preclude definitive therapy, systemic therapy with ADT may be useful as a palliative approach, although this has been associated with shorter overall survival than definitive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link&amp;anchor=H834295#H834295\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\", section on 'Androgen deprivation therapy alone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both transurethral resection of the prostate (TURP) and simple prostatectomy can provide short-term palliation of lower urinary tract obstructive symptoms in men with locally advanced prostate cancer. These procedures may have a role in the elderly and those with substantial comorbidities and a limited life expectancy. However, prolonged local disease control is unlikely. These approaches should never be employed if definitive treatment is the therapeutic goal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24441?source=see_link\">",
"     \"Prostate cancer in elderly patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated by a retrospective series of 52 men with newly diagnosed clinical stage T3 prostate cancer who were treated with either perineal prostatectomy or lesser surgery (transurethral resection of prostate [TURP] or simple prostatectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/26/21930/abstract/56\">",
"     56",
"    </a>",
"    ]. Although 69 percent of men treated with TURP or simple prostatectomy were alive at five years, symptomatic local recurrences were significantly more frequent (75 versus 8 percent with perineal prostatectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4109885\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies following initial definitive treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link&amp;anchor=H7449313#H7449313\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Localized prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with clinically localized, intermediate risk prostate cancer (",
"      <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"       table 2",
"      </a>",
"      ), an adequate life expectancy (greater than 10 years), and without serious comorbidities, we recommend definitive therapy with either external beam radiation therapy (RT) or radical prostatectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men choosing RT as primary therapy, RT may be combined with a short-term (four to six month) course of androgen deprivation therapy (ADT) or brachytherapy. (See",
"      <a class=\"local\" href=\"#H2956464\">",
"       'External beam RT plus ADT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H181128768\">",
"       'Brachytherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men choosing radical prostatectomy, surgery should include pelvic lymph node dissection if the risk of regional lymph node involvement is 2 percent or more. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with a shorter life expectancy (less than 10 years), radiation therapy or active surveillance are appropriate alternatives. (See",
"      <a class=\"local\" href=\"#H181128718\">",
"       'Radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=see_link\">",
"       \"Active surveillance for men with early prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with regionally localized high risk prostate cancer (",
"      <a class=\"graphic graphic_table graphicRef81673 \" href=\"UTD.htm?3/33/3612\">",
"       table 2",
"      </a>",
"      ), we recommend definitive therapy with either external beam radiation therapy (RT) or radical prostatectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Radical prostatectomy should be limited to patients without fixation of their primary tumor. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men choosing external beam RT as primary therapy, we recommend that RT may be combined with long-term (two to three year) course of ADT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If RT is administered as a combination of external beam RT plus brachytherapy, we suggest that a short-term course (four to six months) of ADT be given as well (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2956464\">",
"       'External beam RT plus ADT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H181128768\">",
"       'Brachytherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men choosing radical prostatectomy, surgery should include pelvic lymph node dissection. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men choosing RT as primary therapy, RT should be administered using contemporary conformal techniques to ensure the delivery of a curative dose to the prostate that minimizes rectal and bladder toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Whether the addition of brachytherapy to external beam RT provides benefit beyond that achievable with adequate doses of external beam RT (&ge;72 Gy) plus ADT is unclear. Nevertheless, we suggest using brachytherapy in conjunction with external beam RT and ADT for men with cT3 disease who are appropriate candidates for brachytherapy (",
"      <a class=\"graphic graphic_table graphicRef50303 \" href=\"UTD.htm?2/9/2204\">",
"       table 7",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For men undergoing external beam RT for intermediate, high risk prostate cancer, we suggest whole pelvis RT rather than prostate only RT when the estimated risk of lymph node involvement is greater than 15 percent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, an overall survival advantage has not been demonstrated in this setting, and RT to the prostate only is an appropriate alternative based upon a consideration of the patient's overall situation. (See",
"      <a class=\"local\" href=\"#H181128733\">",
"       'Prostate only versus whole pelvis RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For men with regionally localized intermediate or high risk prostate cancer who choose radical prostatectomy as their primary therapy, we recommend that androgen deprivation therapy (ADT) not be used prior to radical prostatectomy. (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). There is no evidence that this approach improves resectability or long-term outcomes after prostatectomy. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H181129801\">",
"       'Neoadjuvant ADT'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have undergone radical prostatectomy should be reassessed for possible further treatment based upon the results of the histopathologic results and pathologic staging. For patients with adverse histologic features (extracapsular extension, seminal vesicle involvement, positive margins) or a persistent elevation of the serum PSA after surgery, postoperative adjuvant RT may be indicated. (See",
"      <a class=\"local\" href=\"#H181131068\">",
"       'Radical prostatectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=see_link&amp;anchor=H255203697#H255203697\">",
"       \"Pathologic stage T3 and margin positive prostate cancer\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with clinical evidence of lymph node involvement but without distant metastases prior to treatment, we recommend definitive therapy with whole pelvis RT if their overall condition permits aggressive therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We recommend that RT be accompanied by long-term (two to three year) ADT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32353885\">",
"       'Clinical evidence of lymph node involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not using ADT or antiandrogen monotherapy as sole treatment for men with locally advanced disease, except for those patients with significant comorbidity that precludes definitive treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H181130646\">",
"       'Palliative therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/1\">",
"      Roach M 3rd, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 2007; 109:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/2\">",
"      Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/3\">",
"      Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/4\">",
"      Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373:301.",
"     </a>",
"    </li>",
"    <li>",
"     Mottet N, Peneau M, Mazeron J, et al. Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer (abstract #4505). J Clin Oncol 2010; 28:343s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/6\">",
"      Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378:2104.",
"     </a>",
"    </li>",
"    <li>",
"     Mason MD, et al. Final analysis of intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110) (abstract #4509). J Clin Oncol 2012.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on September 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/9\">",
"      Ward JF, Slezak JM, Blute ML, et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/10\">",
"      Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/11\">",
"      Lawton CA, DeSilvio M, Roach M 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/12\">",
"      Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/13\">",
"      Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25:5366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/14\">",
"      Buyyounouski MK, Hanlon AL, Horwitz EM, et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 2005; 61:1291.",
"     </a>",
"    </li>",
"    <li>",
"     www.clinicaltrials.gov (Accessed on August 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/16\">",
"      Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/17\">",
"      Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/18\">",
"      Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/19\">",
"      Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005; 23:800.",
"     </a>",
"    </li>",
"    <li>",
"     Published erratum in JCO 2005; 23:8921.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/21\">",
"      Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/22\">",
"      Laverdi&egrave;re J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/23\">",
"      Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/24\">",
"      Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/25\">",
"      Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/26\">",
"      Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009; 27:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/27\">",
"      Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     Nabid A, et al. High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. J Clin Oncol 2013; 31 (suppl 6; abstr #3).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/29\">",
"      Denham JW, Wilcox C, Joseph D, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol 2012; 13:1260.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/31\">",
"      Heymann JJ, Benson MC, O'Toole KM, et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol 2007; 25:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/32\">",
"      Nanda A, Chen MH, Moran BJ, et al. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/33\">",
"      Rosenthal SA, Bae K, Pienta KJ, et al. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys 2009; 73:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/34\">",
"      D'Amico AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009; 27:3923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/35\">",
"      Hsu IC, Bae K, Shinohara K, et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys 2010; 78:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/36\">",
"      Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/37\">",
"      Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007; 84:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/38\">",
"      Hoskin PJ, Rojas AM, Bownes PJ, et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012; 103:217.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/40\">",
"      Stone NN, Potters L, Davis BJ, et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 73:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/41\">",
"      Koontz BF, Chino J, Lee WR, et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy 2009; 8:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/42\">",
"      Khaksar SJ, Langley SE, Lovell D, Laing RW. Interstitial low dose rate brachytherapy for prostate cancer--a focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 2006; 18:513.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Trials.gov file://www.clinicaltrials.gov/ (Accessed on October 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/44\">",
"      Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/45\">",
"      Powell IJ, Tangen CM, Miller GJ, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol 2002; 168:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/46\">",
"      Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/47\">",
"      Boorjian SA, Karnes RJ, Rangel LJ, et al. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/48\">",
"      Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008; 71:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/49\">",
"      Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/50\">",
"      Critz FA, Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 2004; 172:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/51\">",
"      Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/52\">",
"      Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/53\">",
"      Berglund RK, Tangen CM, Powell IJ, et al. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 2012; 79:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/54\">",
"      Pierorazio PM, Ross AE, Han M, et al. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU Int 2012; 109:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/55\">",
"      Akakura K, Suzuki H, Ichikawa T, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006; 36:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/26/21930/abstract/56\">",
"      Tomlinson RL, Currie DP, Boyce WH. Radical prostatectomy: palliation for stage C carcinoma of the prostate. J Urol 1977; 117:85.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6947 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21930=[""].join("\n");
var outline_f21_26_21930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H511317266\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2952847\">",
"      Benefit of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2951830\">",
"      Clinically localized intermediate risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2951838\">",
"      Regionally localized high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32353885\">",
"      Clinical evidence of lymph node involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181128718\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181128726\">",
"      External beam RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128733\">",
"      - Prostate only versus whole pelvis RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2956464\">",
"      - External beam RT plus ADT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2953368\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H181128747\">",
"      Duration and timing of ADT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3123062\">",
"      Choice of ADT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128754\">",
"      - External beam RT plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128761\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181128768\">",
"      Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128775\">",
"      - HDR brachytherapy plus external beam RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128782\">",
"      - LDR brachytherapy plus external beam RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181128789\">",
"      - Brachytherapy plus ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H181131068\">",
"      RADICAL PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181129794\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181129801\">",
"      Neoadjuvant ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191259\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191458\">",
"      Clinically localized, intermediate risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191266\">",
"      - Radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191273\">",
"      - External beam RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191280\">",
"      - Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1969519\">",
"      - External beam RT plus brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191562\">",
"      Regionally localized, high risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191505\">",
"      - Radical prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191512\">",
"      - External beam RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1191519\">",
"      - Brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1969587\">",
"      - External beam RT plus brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2956530\">",
"      Locally advanced (T3b, T4) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1191287\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2950516\">",
"      Radical prostatectomy versus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181130646\">",
"      Palliative therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4109885\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6947|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1A\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 1B\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/33/3612\" title=\"table 2\">",
"      Pretreat risk stratify prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/12/2252\" title=\"table 3\">",
"      RT plus ADT versus ADT in clinical T3 prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/61/18396\" title=\"table 4\">",
"      Adv main Rx prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/59/18364\" title=\"table 5\">",
"      Disadv main Rx prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/30/10732\" title=\"table 6\">",
"      Contraind main Rx prost CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/9/2204\" title=\"table 7\">",
"      ABS guidelines prost brachyther",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13288?source=related_link\">",
"      Active surveillance for men with early prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=related_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33943?source=related_link\">",
"      Pathologic stage T3 and margin positive prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/55/24441?source=related_link\">",
"      Prostate cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_26_21931="Potential adverse effects of GH therapy";
var content_f21_26_21931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential adverse effects of growth hormone therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Unmet expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibodies to growth hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progression of pre-existing scoliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slipped capital femoral epiphysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Fluid retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudotumor cerebri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transient gynecomastia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increased growth and pigmentation of nevi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Carpal tunnel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arthralgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Second neoplasms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Meningioma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21931=[""].join("\n");
var outline_f21_26_21931=null;
var title_f21_26_21932="Disorders with cancer risk";
var content_f21_26_21932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common hereditary disorders associated with childhood cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Chromosomal Disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Down syndrome",
"       </td>",
"       <td>",
"        Leukemia, testicular, retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Turner syndrome",
"       </td>",
"       <td>",
"        Neurogenic, gonadal, endometrial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klinefelter syndrome",
"       </td>",
"       <td>",
"        Leukemia, germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other sex aneuploidy",
"       </td>",
"       <td>",
"        Retinoblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        XY gonadal dysgenesis",
"       </td>",
"       <td>",
"        Gonadoblastoma, dysgerminoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trisomy 13",
"       </td>",
"       <td>",
"        Teratoma, leukemia, neurogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trisomy 18",
"       </td>",
"       <td>",
"        Neurogenic, Wilm's tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        XYY, XYY mosaic",
"       </td>",
"       <td>",
"        Osteosarcoma, medulloblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Other Genetic Disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xeroderma pigmentosum",
"       </td>",
"       <td>",
"        Basal, squamous cell carcinoma, melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bloom syndrome",
"       </td>",
"       <td>",
"        Leukemia, lymphoma, gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fanconi anemia",
"       </td>",
"       <td>",
"        Leukemia, hepatoma, squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ataxia-telangiectasia",
"       </td>",
"       <td>",
"        Lymphoma, leukemia, Hodgkin's disease, brain, gastric, ovarian, other epithelial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neurofibromatosis type 1",
"       </td>",
"       <td>",
"        Gliomas, malignant peripheral nerve sheath tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberous sclerosis",
"       </td>",
"       <td>",
"        Brain tumors, rhabdomyosarcomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Von Hippel-Lindau disease",
"       </td>",
"       <td>",
"        Renal cell carcinoma, pheochromocytoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21932=[""].join("\n");
var outline_f21_26_21932=null;
var title_f21_26_21933="pMDI priming requirements";
var content_f21_26_21933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Priming requirements for specific pressurized metered dose inhalers (pMDIs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Brand name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to prime",
"       </td>",
"       <td class=\"subtitle1\">",
"        No. of sprays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Short-acting bronchodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Albuterol sulfate HFA",
"       </td>",
"       <td>",
"        ProAir HFA",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        New and when not used for 2 weeks",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proventil",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New and when not used for 2 weeks",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventolin",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New and when not used for 14 days",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pirbuterol",
"       </td>",
"       <td>",
"        Maxair Autohaler&trade;",
"       </td>",
"       <td>",
"        New and when not used for 2 days",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levalbuterol HCl",
"       </td>",
"       <td>",
"        Xopenex HFA&trade;",
"       </td>",
"       <td>",
"        New and when not used for 3 days",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ipratropium bromide HFA",
"       </td>",
"       <td>",
"        Atrovent HFA",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        New and when not used for 3 days",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ipratropium bromide/",
"        <br/>",
"        albuterol sulfate combination",
"       </td>",
"       <td>",
"        Combivent",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New and when not used for 24 hours",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Inhaled glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beclomethasone propionate HFA",
"       </td>",
"       <td>",
"        QVAR&trade;",
"       </td>",
"       <td>",
"        New and when not used for 10 days",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ciclesonide",
"       </td>",
"       <td>",
"        Alvesco",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        New and when not used for 10 days",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Fluticasone propionate",
"       </td>",
"       <td rowspan=\"2\">",
"        Flovent",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not used more than 7 days or if dropped",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triamcinolone acetonide*",
"       </td>",
"       <td>",
"        Azmacort",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        New and when not used for 3 days",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Combination drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Budesonide combined with formoterol",
"       </td>",
"       <td>",
"        Symbicort",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New and not used more than 7 days or if dropped",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Fluticasone combined with salmeterol",
"       </td>",
"       <td rowspan=\"2\">",
"        Advair HFA",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        New",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not used more than 4 weeks or if dropped",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cromolyn sodium",
"       </td>",
"       <td>",
"        Intal",
"        <sup>",
"         &reg;",
"        </sup>",
"        HFA",
"       </td>",
"       <td>",
"        New",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * No longer available in the United States or Canada.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ari A, Hess D, Myers TR, Rau JL. A guide to aerosol delivery devices for respiratory therapists, 2nd ed. American Association for Respiratory Care 2009. A full copy of the report can be obtained through the AARC, available at",
"     <a href=\"file://www.aarc.org/education/aerosol_devices/aerosol_delivery_guide2.pdf\" target=\"_blank\">",
"      file://www.aarc.org/education/aerosol_devices/aerosol_delivery_guide2.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21933=[""].join("\n");
var outline_f21_26_21933=null;
var title_f21_26_21934="Decreasing T with age";
var content_f21_26_21934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal effects of aging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 381px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear segment plots for total T and free T index vs. age are shown for men with T and SHGB values on at least two visits. Each linear segment has a slope equal to the mean of the individual longitudinal slopes in each decade, and is centered on the median age, for each cohort of men from the second to the ninth decade. Numbers in parentheses represent the number of men in each cohort. With the exception of free T index in the ninth decade, segments show significant change in slopes for T or free T index over the entire age range.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harman SM, Metter EJ, Tobin JD, Pearson J. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724. file://jcem.endojournals.org/. Copyright &copy; 2001 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21934=[""].join("\n");
var outline_f21_26_21934=null;
var title_f21_26_21935="Gram stain sputum 9A answer";
var content_f21_26_21935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain in pulmonary tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows no bacteria in an apparently good specimen from a patient with pneumonia. Some bacteria, including Mycobacterium tuberculosis, cannot be seen by Gram stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_26_21935=[""].join("\n");
var outline_f21_26_21935=null;
      